In re Application of.:	§	
	§	
Yoram Reiter	§	
	§	
Serial No.: 10/510,229	§	
	§	
Filed: 10/13/2004	§ Group Art Unit:	1648
	§	
For: ANTIGEN-PRESENTING	§	
COMPLEX-BINDING	§	
COMPOSITIONS AND USES	§	
THEREOF	§	
	§ Attorney Docket:	**28429**
	§	
Examiner: Lucas, Zachariah	§	

Mail Stop ~~BF~~Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF VINCENZO CERUNDOLO UNDER 37 CFR 1.132

I am presently employed as a Principle Investigator where I am a Professor of Immunology at the University of Oxford and Associate Director of the Medical Research Council Human Immunology Unit. I received my Ph.D. degree from the University of Padua, worked as a post-doctoral fellow in the laboratory of Professor Alain Townsend, where I characterized some of the mechanisms controlling the antigen processing and presentation pathways.

My research focuses on the analysis of tumor specific immune response and on the development of novel vaccination strategies. Since the beginning of my career, I have published 170 scientific articles in highly regarded journals and books, and have presented my achievements at many international scientific conferences.

I am a Fellow of the Royal College of Pathologists, and was awarded the Cancer Research Institute, USA Investigator Award. I was elected Fellow to The Academy of Medical Sciences in 2002.

I am considered to be an expert in the field of Immunology.

I have read the Office Action issued with respect to the above-identified patent application.

In this Office Action, the Examiner rejected claims 141-149, 151-155, 158 and 159 under 35 U.S.C. §103(a) as being unpatentable over Reiter (PNAS 94:4631-4636, 1997), further in view of the teachings Andersen et al., (WO 97/02342) who generated antibodies against mouse MHC-peptide complexes but contemplated more. Particularly, the Examiner states that the teachings of Andersen (1997) and Reiter (1997) could be used by any person skilled in the art to generate the antibodies against human MHC-peptide complexes as in the present application by Yoram Reiter.

Being an expert in the field of Immunology, I, Vincenzo Cerundolo, hereby state that the claimed invention, essentially a method of killing or damaging target human cells expressing or displaying a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen using antibodies capable of specifically binding such a complex, is novel and non-obvious over the cited references in that it satisfies a long-felt need which was recognized, persistent and not solved by others at the time of filing of the claimed invention.

I provide herewith documented evidence showing that for more than 15 years prior to the filing date of the invention discussed and claimed in the above-identified patent application, research groups have all failed in generating T-cell receptor (TCR)-like antibodies such as antibodies capable of binding human antigen-presenting molecules and an antigen derived from a pathogen, let alone using them for killing virus infected human cells. In evidence for this I provide herewith several experimental papers all showing failure to obtain TCR-like antibodies for killing virus infected human cells.

Thus, Tamminen WL et al. (Eur. J. Immunol. 1987, 17:999-1006; see, in particular, Abstract; attached herewith) failed to obtain antibodies against MHC-viral peptide complexes.

In addition, Rubin B., et al., 1989 (Res. Immunol. 140:67-74; attached herewith) tested more than 1500 antisera but could not find any antibodies specific for complexes of MHC-insulin peptide (see Page 71, middle paragraph in Rubin et al.).

Chames P., et al., (PNAS, 2000, 97:7969-7974, attached herewith; see in particular Page 7970, left column, first paragraph), state that although highly desired for therapeutic applications, selection of antibodies that recognize MHC-peptide complexes is a difficult task. Chames et al. attempted to identify an antibody with specificity against a human MHC-peptide complex and identified one phage clone displaying Fab G8 which recognized HLA-A1-MAGE-A1 (a melanoma peptide) but not HLA-A1-MAGE-A3 complexes. However, when the soluble G8 Fab fragment, which was purified from the phage clone, was reacted with the target complex, the authors could not find conditions that eluted the antibody without also dissociating the β2m from the HLA-A1 heavy chain, thus, they failed to obtain a TCR-like antibody with specificity to human MHC-peptide complexes (see Page 7972, left column, second column in Chames et al.) which can be used in therapy. In addition, when the purified Fab G8 was immobilized to a surface through its hexahistidine tag, the bound antibody was devoid of affinity sufficient to kill target cells *in vivo*. Moreover, the purified Fab-G8 antibody failed to detect HLA-A1 cells incubated with the MAGE-A1 peptide (see Chames et al., Page 7972, left column, third paragraph), thus could not be used for detecting or killing cells presenting the MHC-peptide complex.

In this regard, Andersen et al. (WO 97/02342) have not provided any further teachings which could advance the use of TCR-like antibodies in human therapy in general and the treatment of virus infections, in particular.

The antibodies described in Andersen et al. (1997) and/or Reiter et al. (1997) are directed against mouse MHC-peptide complexes and not against human MHC-peptide complexes. As the mouse and human MHC molecules exhibit completely different chemical structures, such antibodies (e.g., Fab 13.4) cannot be used for targeting and treating human cells. It is my expert opinion that the antibodies contemplated by Andersen et al. are no more than an expression of a desired result rather than actual conception and reduction to practice.

4

In re Application of: Yoram Reiter
Serial No.: 10/510,229
Filed: 10/13/2004
Office Action Mailing Date: 01/24/2007

Examiner: Lucas, Zachariah
Group Art Unit: 1648
Attorney Docket: 28429

Thus, it is my opinion that all the antibodies described in the prior art (including the publications of Andersen and Reiter) <u>did not satisfy the long-felt need of generating TCR-like antibodies and killing virus infected human cells</u>.

In addition, I further declare that during the years of 2002-2007 my research lab attempted to identify TCR-like antibodies by screening one library against the NY-ESO-$1_{265-274}$/HLA-A2 complexes. However, these efforts resulted in the lack of lysis of NY-ESO-1 positive tumor cells.

It is further my expert opinion that the claimed invention of the above-referenced patent application in fact satisfies the long felt need for antibodies which are specific to human complexes of antigen-presenting molecules and an antigen derived from a pathogen and therefore can be used for killing virus infected human cells.

Thus, the instant application demonstrates, for the first time, the ability to reproducibly generate antibodies with TCR-like specificity for <u>human</u> complexes composed of antigen presenting molecules and peptides derived from a pathogen. The ability of such antibodies to kill virus infected human cells renders them imperative tools for human therapeutic applications (e.g., for killing cells displaying the MHC-peptide complexes).

In re Application of: Yoram Reiter
Serial No.: 10/510,229
Filed: 10/13/2004
Office Action Mailing Date: 01/24/2007

Examiner: Lucas, Zachariah
Group Art Unit: 1648
Attorney Docket: 28429

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United states Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

16th July 2007

_____

Vincenzo Cerundolo

Enc.:

CV of Vincenzo Cerundolo

References:

- Tamminene WL., et al., Eur. J. Immunol. 1987, 17:999-1006;
- Rubin B., et al., 1989, Res. Immunol. 140:67-74;
- Chames P., et al., PNAS, 2000, 97:7969-7974;

Curriculum Vitae

Name:	Vincenzo Cerundolo
Title:	Professor of Immunology
Nationality:	Italian
Date of birth:	20th December 1959
Work address:	Nuffield Department of Medicine
	University of Oxford
	Weatherall Institue of Molecular Medicine
	John Radcliffe Hospital, Headley Way
	OXFORD OX3 9DS
	UK

T: +44 (0)1865 222 412
F: +44 (0)1865 222 502
Email: vincenzo.cerundolo@imm.ox.ac.uk

Qualifications

2002	Fellow Royal College of Pathologists (FRCPath)
2002	Fellow of the Academy of Medical Sciences (FMedSci)
2000	Professor of Immunology, University of Oxford
1999	MA, University of Oxford
1995	Membership of Royal College of Pathologists (MRCPath)
1993	General Medical Council Registration (No. 4066655)
1987	PhD in Immunology, University of Padua, Italy
1984	Full registration as medical practitioner in Italy
1984	Medical Degree (cum laude), University of Padua, Italy

Appointments

Since 2004	Associate Director, MRC Human Immunology Unit, Oxford
Since 2001	Professor, University of Oxford
Since 2000	Director, Tumour Immunology CRUK Programme, University of Oxford
Since 1996	Honorary Consultant, Medical Oncology, Oxford Radcliffe Hosptials NHS Trust
1996 – 2001	Medical Research Council Clinical Fellow, Institute of Molecular Medicine, Oxford
1990 – 1995	Medical Research Council Post-Doctoral Fellow, Institute of Molecular Medicine, Oxford
1988 – 1989	Fellow of European Molecular Biology Organization (EMBO), Institute of Molecular Medicine, Oxford
1984 – 1987	Residence in Oncology, Institute of Oncology, University of Padua, Italy
1980 – 1984	Elective in Immunology, Department of Immunology, University of Padua, Italy

Fellowships

2002	Fellow Royal College of Pathologists (FRCPath)

2001	Fellow Academy of Cancer Immunology
1997	Research Fellow, Merton College, Oxford
1996	Clinical Senior Fellow, Medical Research Council
1988	Long-term Fellow, European Molecular Biology Organisation (EMBO)
1984	Fellow, Associazione Italiana per la Ricerca sul Cancro (AIRC)

Prizes

1997	Investigator Award from the Cancer Resarch Institute, USA
1984	Prize Virgilio Chinni for PhD thesis at Padua Medical School, Italy

170. **Cerundolo V**, and Salio M. Harnessing NKT cells for therapeutic applications. *Curr Top Microbiol Immunol.* 2007;314:325-40

169. Held G, Wadle A, Dauth N, Stewart-Jones G, Sturm C, Thiel M, Zwick C, Diechmann D, Schuler G, Hoogenboom HR, Lévy F, **Cerundolo V**, Pfreundschun M, Renner C. MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A0201-restricted, Melan-A-derived peptide after active intracellular processing. *Eur J Immunol.* 2007; 37:2008-2017

168. McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch S, Illarionov PA, Bossi G, Denkberge G, Tarlton A, Schmidt RR, Reiter Y, Griffiths G, van der Merwe A, Besra GS, Jones EY, Batista F, **Cerundolo V**. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell lTCR and the threshold of NKT cell activation. *J Exp Med.* 2007 May; 204(5):1131-1144

167. Wooldridge L, Lissina A, Vernazza J, Gostick E, Laugel B, Hutchinson SL, Mira F, Dunbar PR, boulter JM, Glick M, **Cerundolo V**, van den Berg HA, Sewell AK. Enhaned immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. *Eur J Immunol.* 2007 May; 37(5):1323-33

166. Ling KL, Pratap SE, Bates GJ, Mortensen NJ, George BD, Warren BF, Piris J, Ronacador G, Fox SB, Banham AH, **Cerundolo V**. Increased populations of regulatory T cells in peripheral blood and tummour infiltrating lymphocytes in colorectal cancer patients. *Cancer Immunity.* 2007 March 28;7:7.

165. Speak AO, Salio M, Neville DC, Fontaine J, prestman DA, Platt N, Heare T, Butters TD, Dwek RA, Trottein F, Exley MA, **Cerundolo V** and Platt FM. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexoylceramide in mammals. *Proc Natl Acad Sci USA.* 2007 Apr 3;104(14):5971-6.

164. Probusky S, Speak AO, Luckow B, **Cerundolo V**, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. *Proc Natl Acad Sci USA.* 2007 Apr 3;104(14):5977-82

163. Ling KL, Dulphy N, Bahl P, Salio M, Maskell K, Piris J, Warren BF, George BD, Mortensen NJ, **Cerundolo V**. Modulation of CD103 expression on human colon carcinoma-specific CTL. *J Immunol* 2007 Mar 1; 178(5):2908-15

162. Herman, JF, Silk JD, Gileadi U, Masri SH, Shepherd D, Farrand JK, Salio M, **Cerundolo V**. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. *J Immunol.* 2007 Mar 1; 178(5):2721-9.

161. Chiu C, Heaps AG, **Cerundolo V**, McMichael AJ, Banham CR, Callan MF. Early acquisition of cytolytic function and transcriptional changes in a primary CD8+ T-cell resposne in vivo. *Blood.* 2007 Feb 1;109(3);1086-94. Epub 2006 Sep 21

160. Gadola SD, Silk JD, Jeans A, Illarionov PA, Salio M, Besra GS, Dwek R, Butters TD, Platt FM, **Cerundolo V**. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. *J Exp Med.* 2006 Oct2; 203(10):2293-303. Epub 2006 Sep 18

159. **Cerundolo V**, de la Salle H. Description of HLA class I- and CD8-deficient patients: Insights into the function of cytotoxic T lylmphocytes and NK cells in host defense. *Semin Immunol.* 2006 Dec;18(6):330-6

158. Mosley AJ, Meekings KN, McCarthy C, Shepherd D, **Cerundolo V**, Maxitscheck R, Tanaka Y, Taylor GP, Bangham CR. Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell in anti-viral function in HTLV-I infection. *Blood.* 2006 Dec15: 108(12): 3801-7

157. Palmowski MJ, Gileadi U, Salio M, Gallimore A, Millrain M, James E, Addey C, Scott D, Dyson J, Simpson E, **Cerundolo V**. Role of Immunoproteasomes in Cross-Presentation. *J Immunol.* 2006 Jul 15;177(2):983-990.

156. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jager E, Cameron BJ, Lissin N, Vyas P, Chen JL, **Cerundolo V**, Jakobsen BK. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. *J Immunol.* 2006 Jun 15;176(12):7308-16.

155. Lau YS, Sabokbar A, Giele H, **Cerundolo V**, Hofstetter W, Athanasou, NA. Malignant melanoma and bone resorption. *Bri J Cancer.* 2006;94:1496-1503

154. Quiroga I, Salio M, Koo DDH, Cerundolo L, Shepherd D, **Cerundolo V**, Fuggle SV. Expression of MHC Class I-Related Chain B (MICB) Molecules on Renal Transplant Biopsies. *Transplantation.* 2006;82(8):1196-1203

153. Gadola S, Koch M, Marles-Wright J, Lissin N, Shepherd D, Matulis G, Harlos K, Villige PM, Stuart D, Jakobsen B, **Cerundolo V**, and Jones Y. Structure and binding kinetics of three different human CD1d-α-galactosylceramide - specific T cell Receptors. *J Exp Med.* 2006;203(3):699-710

152. Zhang J, Raper A, Sugita N, Hingorani R, Salio M, Palmowski MJ, **Cerundolo V**, Crocker PR. Characterisation of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. *Blood.* 2006;107(9):3600-3608

151. Chen N, McCarthy C, Drakesmith H, Li D, **Cerundolo V**, McMichael AJ, Screaton GR, Xu XN. HIV-1 down-regulates the expression of CD1d via Nef. *Eur J Immunol.* 2006;36:278-286

150. Kotsianidis I, Silk JD, Spanoudakis E, Patterson S, Almeida A, Schmidt RR, Tsatalas C, Bourikas G, **Cerundolo V**, Roberts IA, Karadimitris A. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. *Blood.* 2006;107(8):3138-3144

149. Smith C, Mirza F, Pasquetto V, Tscharke D, Palmowski M, Dunbar R, Sette A, Harris AL, **Cerundolo V**. Immunodominance of poxviral-specific CTL in a human trial of recombinant Modified Vaccinia Ankara. *J Immunol.* 2005 Dec 15;175(12):8431-7

148. Trautmann L, Rimbert M, Echasserieau K, Saulquin X, Neveu B, Dechanet J, **Cerundolo V**, Bonneville M. Selection of T Cell Clones Expressing High-Affinity Public TCRs within Human Cytomegalovirus-Specific CD8 T Cell Responses. *J Immunol.* 2005 Nov 1;175(9):6123-32.

147. Pasquetto V, Bui HH, Giannino R, Mirza F, Sidney J, Oseroff C, Tscharke DC, Irvine K, Bennink JR, Peters B, Southwood S, **Cerundolo V**, Grey H, Yewdell JW, Sette A. HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products. *J Immunol.* 2005 Oct 15;175(8):5504-15

146. Patterson S, Kotsianidis I, Almeida A, Politou M, Rahemtulla A, Matthew B, Schmidt RR,

Cerundolo V, Roberts IA, Karadimitris A. Human invariant NKT cells are required for effective in vitro alloresponses. *J Immunol.* 2005 Oct 15;175(8):5087-94.

145. Milicic A, Price DA, Zimbwa P, Booth BL, Brown HL, Easterbrook PJ, Olsen K, Robinson N, Gileadi U, Sewell AK, **Cerundolo V**, Phillips RE. CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. *J Immunol.* 2005 Oct 1;175(7):4618-26

144. Ait-Tahar K, **Cerundolo V**, Banham AH, Hatton C, Blanchard T, Kusec R, Becker M, Smith GL, Pulford K. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. *Int J Cancer.* 2005 Aug 19;

143. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, Fersht AR, Besra GS, Schmidt RR, Jones EY, **Cerundolo V**. The crystal structure of human CD1d with and without alpha-galactosylceramide. *Nat Immunol.* 2005 Aug;6(8):819-26.

142. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, **Cerundolo V**, Powrie F, Banham AH. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. *Eur J Immunol.* 2005 Jun;35(6):1681-91

141. Salio M and **Cerundolo V** The bell tolls for dying infected cells. *Current Biology.* 2005 May 10;15(9):R336-9

140. Manders P. M. , Hunter P. , Telaranta A., Carr J., Marshall J., Carrasco M., Yusuke Murakami Y., Palmowski M., **Cerundolo V.**, Kaech S., Ahmed R., Fearon D.T. BCL6b Mediates the Enhanced Magnitude of the Secondary Response of Memory CD8$^+$ T Lymphocytes. *Proc. Natl. Acad. Sci.(USA).* 2005 May 24;102(21):7418-25.

139. Chen J-L, Stewart-Jones G., Bossi G., Lissin M.N.,Wooldridge L., Choi E. , Held G., Dunbar P.R., Esnouf R., Sami M. , Boulter J.M., Rizkallah P., Renner C., , Sewell A., van der Merwe P.A., Jakobsen B.K., Griffiths G., Jones EY, **Cerundolo V**. Structural and kinetic basis for heightened immunogenicity of T-cell vaccines. *J. Exp. Medicine.* 2005 Apr 18;201(8):1243-55

138. Maczek C, Berger TG, Schuler-Thurner B, Schultz ES, Hamann A, Dunbar, PR, **Cerundolo V**, Steinkasserer A, Schuler G. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide- specific CTL in HLA-A*0201 melanoma patients. *Int J Cancer.* 2005 Jun 20;115(3):450-5

137. Renneson J, Salio M, Mazouz N, Goldman, Marchant A. and **Cerundolo V**. Mature dendritic cells differentiated in the presence of IFN-b and IL-3 prime functional antigen-specific CD8$^+$ T cells. *Clinical Experimental Immunology* 2005 Mar;139(3):468-75.

136. Collins MK, **Cerundolo V**. Gene therapy meets vaccine development. *Trends Biotechnol.* 2004 Dec;22(12):623-6

135. Silk, J. Hermans, I, Gileadi, U., Chong, W., Shepherd,D., Salio, M., Mathew, B., Schmidt, R.R., Lunt, S. Williams, K., Stratford, I., Harris A., and **Cerundolo V**. Utilizing the adjuvant properties of CD1d-dependent NKT cells in T cell-mediated immunotherapy. *J Clinical Investigation.* 2004 Dec;114(12):1800-11.

134. Barnes E, Salio M, **Cerundolo V**, Medlin J, Murphy S, Dusheiko G, Klenerman P. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. *Antimicrob Agents Chemother.* 2004 Sep;48(9):3382-9

133. Smith, C., Dunbar, R., Mirza F., Palmowski JM., Shepherd D., Gilbert S., Coulie P., Schneider J., Hoffman E., Hawkins R., Old L., Harris A., and **Cerundolo, V.** Recombinant Modified Vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. *International Journal of Cancer.* 2005 Jan 10;113(2):259-66.

132. Smith D.C., Salio M, J. Lord M, Roberts L.M and **Cerundolo V** . Lack of dendritic cell maturation by the plant toxin ricin. *Eur. J. of Immunol.* Aug;34(8):2149-57, 2004

131. Markel, G., Achdout, H., Katz, G., Ling, K-L, Salio, M., Gruda, R., Gazit, R., Mizrahi, S., Hanna, J., Gonen-Gross, T., Arnon, T., Lieberman, N., Stren, N., Nachmias, B., Blumberg, R., Steuer, G., Blau, H., **Cerundolo, V.**, Mussafi, H., Mandelboim. O. Biological function of the soluble CEACAM1 and implications in TAP2 deficient patients. *Eur J of Immunol.* Aug;34(8):2138-48, 2004.

130. Salio, M., Palmowski, M. J., Atzberger, A., Hermans I.F., and **Cerundolo V**. CpG-matured murine Plasmacytoid Dendritic Cells: professional antigen presenting cells capable of *in vivo* priming functional antigen-specific CD8 T cell responses to endogenous but not exogenous antigens. *J Exp Medicine.* Feb 16;199(4):567-579, 2004

129. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, Dunbar PR, Shepherd D, **Cerundolo V**, Emery V, Griffiths P, Conlon C, McMichael AJ, Richman DD, Rowland-Jones SL, Appay V. Immune Activation and CD8(+) T-Cell Differentiation towards Senescence in HIV-1 Infection. *PLoS Biol.* Feb;2(2):E20, 2004

128. **Cerundolo, V.**, Hermans, I, Salio M. Dendritic cells: a journey from the laboratory to the clinic. *Nature Immunology* 5(1):7-10, 2004.

127. Batuwangala, T., Shepherd, D., Gadola, S., Gibson, K., Zaccai, N., Fersht, A., Besra, G.S., Cerundolo, V., Jones, Y. The crystal structure of CD1b with a bound bacterial glycolipid. *J Immunol.* 15;172(4):2382-2388, 2004

126. Palmowski MJ, Lopes L, Ikeda Y, Salio M, **Cerundolo V** and Collins MK. Intravenous Injection of Lentiviral Vector Encoding NY-ESO-1 induces effective CTL responses. *J Immunol.* 2004 Feb 1; 172(3): 1582-7

125. Hermans I.F., Silk J.D., Yang J., Palmowski, M.J., Gileadi U., McCarthy C., Salio M., Ronchese F. and **Cerundolo V**. The VITAL assay: A versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. *J Immunological Methods* 2004 Feb;285(1):25-40

124. Faroudi M, Utzny C, Salio M, **Cerundolo V**, Guiraud M, Muller S, Valitutti S. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation threshold. Proc Natl Acad Sci U S A. 100(24):14145-50, 2003

123. Markel, G., Mussaffi, H., Ling, K-L., Salio, M., Gadola, S., Steuer, G., Blau, H., Achdout, H., de Miguel, M., Gonen-Gross, T., Hanna, J., Arnon, T., Qimron, U., Volovitz, I., Eisenbach, L. Blumberg, R.S., Porgador, A., **Cerundolo, V.**, Mandelboim, O. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 1;103(5):1770-8

122. Wooldridge L, Hutchinson SL, Choi EM, Lissina A, Jones E, Mirza F, Dunbar PR, Price DA, **Cerundolo V**, Sewell AK. Anti-CD8 antibodies can inhibit or enhance peptide-MHC

class I (pMHCI) multimer binding: This is paralleled by their effects on cytotoxic T lymphocyte activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J. Immunol. 2003 Dec 15;171(12):6650-6660

121. Smith C, Dulphy N., Salio M, **Cerundolo V**. Immunotherapy for colorectal cancer. British Medical Bulletin, Advances in colorectal cancer. Oxford University Press. 2002;64:181

120. Hermans I.F., Chong T.W., Palmowski M.J., Harris A.L. and **Cerundolo V**. Synergistic effect of metronomic dosing of cyclophosphamide with specific anti-tumour immunity in a murine melanoma model. Cancer Research 2003 Dec 1;63(23):8408-13.

119. Hermans I.F, Silk J.D, Gileadi U, Salio M, Ritter G, Schmidt R, Harris A, Old L, and **Cerundolo V**. NKT cells can modulate CD4$^+$ and CD8$^+$ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunology. 2003 Nov 15;171(10):5140-5147.

118. Choi E, Chen J, Salio M, Lissin N, Hermans I, Silk J.D, Mirza F, Palmowski M.J, Dunbar P.R, Jakobsen B.K, Sewell A.K, **Cerundolo V**. High avidity antigen specific CTL identified by CD8 independent tetramer staining. J. Immunology. 2003 Nov 15;171(10):5116-5123

117. Salio M, Dulphy N, Renneson J, Herbert M, McMichael A, Marchant A, **Cerundolo V**. Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. Int Immunol. 2003 Oct;15(10):1265-73

116. Yang J.Q, Singh A.K, Wilson M.T, Satoh M, Stanic A.K, Park J, Hong S, Gadola S, Mizutani A, Kakumanu S.R, Reeves W.H, **Cerundolo V**, Joyce S, Van Kaer L, Singh R.R. J. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis.J. Immunology 2003 Aug 15;171(4):2142-53

115. Schultz H, Schinke S, Weiss J, **Cerundolo V**, Gross WL, Gadola S. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibilit to Gram-negative bacterial infections. Clin Exp Immunol. 2003Aug; 133(2):252-9

114. Gadola SD, Karadimitris A, Zaccai NR, Salio M, Dulphy N, Shepherd D, Jones EY, Cerundolo V. Generation of CD1 tetramers as a tool to monitor glycolipid-specific T cells. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):875-7

113. Marchant A, Appay V, Van Der Sande M, Dulphy N, Liesnard C, Kidd M, Kaye S, Ojuola O, Gillespie GM, Vargas Cuero AL, **Cerundolo V**, Callan M, McAdamKP, Rowland-Jones SL, Donner C, McMichael AJ, Whittle H.Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest. 2003 Jun;111(11):1747-55

112. Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, **Cerundolo V**, Storkus WJ, Das PK. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest. 2003 May;83(5):683-95

111. Jones, E., Price, DA, Dahm-Vicker M, **Cerundolo V**, Klenerman P, Gallimore A. The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology. 2003 May;109(1):68-75

110. Lautscham G, Haigh T, Mayrhofer S, Taylor G, Croom-Carter D, Leese A, Gadola S, **Cerundolo V**, Rickinson A, Blake N. Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent

membrane protein 2. J Virol. 2003 Feb;77(4):2757-61.

109. Salio, M., Cella., M., Facchetti, F., Shepherd, D., Colonna, M., **Cerundolo, V.** Plasmacytoid Dendritic cells prime IFN-γ secreting Melan-A specific CD8 lymphocytes and are found in melanoma lesions. Eur. J. Immunol. 2003 Apr;33(4):1052-62

108. Lucas M, Gadola S, Meier U, Young NT, Harcourt G, Karadimitris A, Coumi N, Brown D, Dusheiko G, **Cerundolo V**, Klenerman P. Frequency and Phenotype of Circulating Valpha24/Vbeta11 Double-Positive Natural Killer T Cells during Hepatitis C Virus Infection. J Virology. 2003 Feb 1;77(3):2251-2257

107. Lautscham, G., Haigh, T., Mayrhofer, S., Croom-carter, D., Leese, A., Gadola, S., **Cerundolo, V.**, Richinson, A., Blake, N. A TAP-independent CD8+ T cell epitope from EBV latent membrane protein 2 requires the immunoproteasome for it's processing. J. Virology. 2003 Feb;77(4):2757-61

106. Palmowski M, Salio M, Dunbar RP, **Cerundolo V.** The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev. 2002 Oct;188(1):155-63

105. Simon A.K., Gallimore, A., Jones, E., Sawitzki, B., **Cerundolo, V.**, Screaton, G. R. Fas ligand breaks tolerance to self antigens and induces tumour immunity mediated by antibodies. Cancer Cell 2002 Oct;2(4):315-22

104. Gadola, S.D., Zaccai, N. R., Harlos, K., Shepherd, D., Ritter, G., Schmidt, R.R., Jones, Y., **Cerundolo, V.** Structure of human CD1b with bound ligands at 2.3Å, a maze for alkyl chains. *Nature Immunology* 2002, 3:721

103. Smith, D.C., Gallimore, A., Jones , E., Roberts, E., Lord, J.M., Deeks, E., **Cerundolo, V.**, Roberts* M. L. Exogenous peptides delivered by ricin require processing by signal peptidase for TAP-independent MHC class I-restricted presentation. 2002 J. of Immunology 2002 Jul 1;169(1):99-107.

102. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, **Cerundolo V**, McMichael AJ, Rowland-Jones SL. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002 Apr;8(4):379-85

101. Glick M, Price DA, Vuidepot AL, Andersen TB, Hutchinson SL, Laugel B, Sewell AK, Boulter JM, Dunbar PR, **Cerundolo V**, Oxenius A, Bell JI, Richards WG, Jakobsen BK. Novel CD8+ T cell antagonists based on beta 2 microglobulin. J Biol Chem. 2002 Mar 25

100. Choi , E.M., Palmowski, M., Chen J., and **Cerundolo, V.**, The use of chimeric A2K^b tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice. Journal Immunological Methods 2002 Oct 1;268(1):35

99. Klenerman P., **Cerundolo, V.**, and Dunbar P.R. T Cell Immunology: new tales from new tools. *Nature Rev Immunol.* 2002 Apr;2(4):263-72.

98. Gadola, S.D. Dulphy, N., Salio, M., and **Cerundolo, V.**, Vα24-JαQ-independent CD1d-restricted Recognition of α-Galactosylceramide by Human CD4⁺ and CD8αβ⁺ T Lymphocytes. 2002, J. Immunology, 168(11):5514-20

97. Palmowski, M., Choi, E., Hermans, I., Gilbert, S., Chen, J-L., Gileadi, U., Salio, M., Van Pel, A., Man, S., Bonin, E., Liljestrom P., Dunbar, P.R., **Cerundolo, V**. Competition between cytotoxic T lymphocytes narrows the immune response induced by prime-boost vaccination protocols. 2002, *J Immunology*, 168 (9): 4391-4398

96. Jones, E., Dahm-Vicker, M., Simon, A.K., Green, A., Powrie, F., **Cerundolo, V.**, and Gallimore, A. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity 2002; 2:1. URL: http://www.cancerimmunity.org/v2p1/020201.htm95

95. Hemelaar J, Bex F, Booth B, **Cerundolo V**, McMichael A, Daenke S. Human T-cell leukemia virus type 1 Tax protein binds to assembled nuclear proteasomes and enhances their proteolytic activity. J Virol. 2001 Nov;75(22):11106-15. 94

94. Evans, M., Borysiewicz, L.K., Evans, A., Rowe, M., Jones, M., Gileadi, U., **Cerundolo, V.**, and Man, S. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. Journal of Immunology 2001 Nov 1;167(9):5420-8.

93. Smith C, and **Cerundolo V**. Immunotherapy of melanoma. Immunology. 2001 Sep;104(1): 1-7.

92. Palmowski M., and **Cerundolo, V.**, Monitoring of cytotoxic T cells by HLA Class I tetramers. ASHI Quaterly XXX

91. Kelleher AD, Booth BL Jr, Sewell AK, Oxenius A, **Cerundolo V**, McMichael AJ, Phillips RE, Price DA. Effects of retroviral protease inhibitors on proteasome function and processing of hiv-derived mhc class i-restricted cytotoxic t lymphocyte epitopes. AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1063-6

90. Propato, A., Cutrona, G., Francavilla, V., Ulivi, M., Schiaffella, E., Landt, O., Dunbar, P.R., **Cerundolo, V.**, Ferrarini, M., Barnaba, V. Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine 7:807-813, 2001

89. Xu X, Purbhoo MA, Chen N, Mongkolsapaya J, Cox JH, Meier U, Tafuro S, Dunbar PR, Sewell AK, Hourigan CS, Appay V, **Cerundolo V**, Burrows SR, McMichael AJ, Screaton GR. A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using alpha3 Domain Mutants of MHC Class I/Peptide Complex. Immunity. 2001 May;14(5):591-602

88. Salio, M., Shepherd, D., Dunbar, P.R., Palmowski, M., Murphy, K., Wu, L., and **Cerundolo, V**. Mature dendritic cells prime functionally superior melan-A specific CD8+ lymphocytes as compared with non-professional antigen presenting cells. 2001 J. Immunology 167:1188-1197.

87. Karadimitris, A., Gadola, S., Altamirano, M., Brown, D., Woolfson, A., Klenerman, P., Chen, J-L., Koezuka, Y., Roberts, I.,Dusheiko, G., Milstein , C., Fersht, A., Luzzatto, L., and **Cerundolo, V**. Human CD1d/Glycolipid Tetramers generated By In Vitro Oxidative Refolding Chromatography. *Proc Natl Acad Sci U S A*. 2001 Mar 13;98(6):3294-3298.

86. **Cerundolo V**. Use of major histocompatibility complex class I tetramers to monitor tumor-specific cytotoxic T lymphocyte response in melanoma patients. Cancer Chemother Pharmacol. 2000;46 Suppl:S83-5.

85. Romero P, Pittet MJ, Valmori D, Speiser DE, **Cerundolo V**, Lienard D, Lejeune F, Cerottini JC. Immune monitoring in cancer immunotherapy. Ernst Schering Res Found Workshop. 2000;(30):75-97

84. Oelke M, Kurokawa T, Hentrich I, Behringer D, **Cerundolo V**, Lindemann A, MacKensen A. Functional characterization of CD8+ antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology. Scand J Immunol. 2000 Dec;52(6):544-9.

83. Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, **Cerundolo V**, Ritter G, Chen YT, Knuth A, Old LJ. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10917-22.

82. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, **Cerundolo V**, von Den Driesch P, Knop J, Brocker EB, Enk A, Kampgen E, Schuler G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000 Sep 15;165(6):3492-6

81. P. R. Dunbar, C. L. Smith, D. Chao, M. Salio, D. Shepherd, F. Mirza, M.Lipp, A. Lanzavecchia, F. Sallusto, A. Evans, R. Russell-Jones, A. L. Harris, **V. Cerundolo**. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumour-specific immune response. J. Immunology 2000, 165:6644-6652.

80. Valmori, D., Dutoit, V., Liénard, D., Lejeune, F., Speiser, D., Rimoldi, D., **Cerundolo, V.,** Dietrich,P., Cerottini, J-C., and Romero P., Tetramer-Guided Analysis of TCR -Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients. J. Immunol. , 2000, 165: 533-538.

79. Appay V., Dunbar. P.R., **Cerundolo, V.,** McMichael A., Czaplewski L., Rowland-Jones, S. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. International Immunology 2000 Aug;12(8):1173-82.

78. Gadola, S.D., Moins-Teisserenc, H.T., Trowsdale, J., Gross, W.L., **Cerundolo, V**. TAP deficiency syndrome. Clinical and Experimental Immunology 2000 Aug;121(2):173-8.

77. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, **Cerundolo V**, Anichini A. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res. 2000 Jul 1;60(13):3559-68.

76. Larsson M, Messmer D, Somersan S, Fonteneau JF, Donahoe SM, Lee M, Dunbar PR, **Cerundolo V**, Julkunen I, Nixon DF, Bhardwaj N. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol. 2000 Aug 1;165(3):1182-90.

75. Chen, J., Dunbar, R., Gileadi, U., jager, E., Gnjatic S., Nagata Y., Stockert, E., Panicali, D.L., Chen Y-T., Knuth, A., Old, L.J., **Cerundolo, V**. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor reactive cytotoxic T lymphocytes. J. Immunol. 165:948-955, 2000

74. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, **Cerundolo V**, Dupont B, Chen YT, Old LJ, Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and

cellular immune responses. <u>Proc Natl Acad Sci U S A.</u> 2000 Apr 25;97(9):4760-5

73. Oelke M., Moehrle U., Chen JL., Behringer D., **Cerundolo V.**, Lindermann A., Mackensen A. Generation and purification of CD8+ melan A-specific cytotoxic T lymphocytes for an adoptive transfer in tumor immunotherapy. <u>Clinical Cancer Research</u> 6:1997-2005, 2000

72. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, **Cerundolo V**, Borysiewicz LK, McMichael AJ, Wilkinson GW. Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40. <u>Science</u> 2000 Feb 11;287(5455):1031

71. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Lienard D, **Cerundolo V**, Cerottini JC, Romero P . Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A related peptide Analogue. <u>J Immunol</u> 2000 Jan 15;164(2):1125-1131

70. Ogg GS, Dunbar PR, **Cerundolo V**, McMichael AJ, Savage P. Sensitisation of tumour cells to lysis by class I/peptide complexes virus-specific CTL using antibody-targeted MHC class I tetramers . <u>Br. J. Cancer</u> 2000 Mar;82(5):1058-62

69. Salio, M, **Cerundolo V.**, Lanzavecchia A. Dendritic cell maturation is induced by Mycoplasma infection but not by necrotic cells. <u>Eur. J. Immunol</u> 2000 Feb;30(2):705-708

68. Youde J.S., Dunbar P.R., Evans E.M.L., Fiander A.N., Borysiewicz L.K., **Cerundolo V.**, Man S. Use of fluoresceinated HLA-A*0201/HPV16E7 peptide complexes to isolate rare human CTL recognising endogenous HPV antigens. <u>Cancer Research</u> 2000 Jan 15;60(2):365-71

67. Valmori D, Fonteneau JF, Valitutti S, Gervois N, Dunbar R, Lienard D, Rimoldi D, **Cerundolo V**, Jotereau F, Cerottini JC, Speiser DE, Romero P. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. <u>Int Immunol</u> 1999 Dec;11(12):1971-1980

66. Mackensen A, Herst B., Chen J-L., Kohler G., Noppen C., Herr W., Spagnoli G.C., **Cerundolo V.**, Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. <u>International Journal of Cancer</u> (in press) 1999

65. **V. Cerundolo.** Use of MHC class I tetramers to monitor tumor specific CTL responses in melanoma patients. <u>Cancer , Chemotherapy and Pharmacology</u> (CCP) 46:83, 2000

64, Moins-Teisserenc HT, Gadola S, Cella M, Dunbar PR, Exley A, Blake A, baycal C, Lambert J, Bigliardi P, Willemsen M, Jones M, Buechner S, Colonna M, Gross WL, **Cerundolo V**. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class I molecules. *The Lancet* 354: 1598-1603, 1999

63. Gileadi U, Moins-Teisserenc HT, Correa I, Booth B Jr, Dunbar PR, Sewell AK, Trowsdale J, Phillips RE, **Cerundolo V**. Generation of an Immunodominant CTL epitope is affected by proteasome sununit composition and stability of the antigenic protein. <u>J. Immunol</u> Dec 1;163(11):6045-6052, 1999.

62. Whelan JA, Dunbar PR, Price DA, Purbhoo MA, Lechner F, Ogg GS, Griffiths G, Phillips RE, **Cerundolo V**, Sewell AK. Specificity of CTL Interactions with Peptide-MHC Class I Tetrameric Complexes Is Temperature Dependent. <u>J Immunol</u> 1999 Oct 15;163(8):4342-4348

61. **Cerundolo V**. T cells work together to fight cancer. <u>Curr Biol</u> 1999 Sep 23;9(18):R695-R697

60. Speiser DE, Pittet MJ, Valmori D, Dunbar R, Rimoldi D, Lienard D, MacDonald HR, Cerottini JC, **Cerundolo V**, Romero P. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. <u>J Exp Med</u> 1999 Sep 20;190(6):775-82

59. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, **Cerundolo V**, Cerottini JC, Romero P. High Frequencies of Naive Melan-A/MART-1-specific CD8(+) T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (HLA)-A2 Individuals. <u>J Exp Med</u> 1999 Sep 6;190(5):705-716

58. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, **Cerundolo V**, Parmiani G. An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CTL)-defined,Melanocyte-specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-specific CTLs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions. <u>J Exp Med</u> 1999 Sep 6;190(5):651-668

57. Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, Dunbar R, **Cerundolo V**, Cerottini JC, Romero P. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. <u>Cancer Res</u> 1999 Aug 15;59(16):4050-5

56. Gileadi U, Gallimore A, Van der Bruggen P, **Cerundolo V**. Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. <u>Eur J Immunol</u> 1999 Jul;29(7):2213-22

55. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, **Cerundolo V**, Nixon DF, Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. <u>J Clin Invest</u> 1999 Jul;104(2):173-80

54. Noakes KL, Teisserenc HT, Lord JM, Dunbar PR, **Cerundolo V**, Roberts LM. Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. <u>FEBS Lett</u> 1999 Jun 18;453(1-2):95-9

53. Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, **Cerundolo V**, MacDonald HR, Cerottini JC, Romero P.CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. <u>Eur J Immunol</u> 1999 Jun;29(6):1990-9

52. Sewell AK, Price DA, Teisserenc H, Booth BL Jr, Gileadi U, Flavin FM, Trowsdale J, Phillips RE, **Cerundolo V**. IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. <u>J Immunol</u> 1999 Jun 15;162(12):7075-9

51. Dunbar PR, Chen JL, Chao D, Rust N, Teisserenc H, Ogg GS, Romero P, Weynants P, **Cerundolo V**. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. <u>J Immunol</u> 1999 Jun 15;162(12):6959-62

50. Bachmann MF, Gallimore A, Linkert S, **Cerundolo V**, Lanzavecchia A, Kopf M, Viola A. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naïve and memory T cells. <u>J Exp Med</u> 1999 May 17;189(10):1521-30

49. Valmori D, Pittet MJ, Rimoldi D, Lienard D, Dunbar R, **Cerundolo V**, Lejeune F, Cerottini JC, Romero P . An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res 1999 May 1;59(9):2167-73

48. Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, **Cerundolo V**, Levy F . Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 1999 Mar 15;189(6):895-906

47. Collins EJ, Booth BL Jr, **Cerundolo V**. Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition. J Immunol 1999 Jan 1;162(1):331-7

46. Young NT, Mulder A, **Cerundolo V**, Claas FH, Welsh KI. Expression of HLA class I antigens in transporter associated with antigen processing (TAP)-deficient mutant cell lines. Tissue Antigens 1998 Oct;52(4):368-73

45. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, **Cerundolo V**. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998 Nov 2;188(9):1641-50

44. Young NT, Rust NA, Dallman MJ, **Cerundolo V**, Morris PJ, Welsh KI. Independent contributions of HLA epitopes and killer inhibitory receptor expression to the functional alloreactive specificity of natural killer cells. Hum Immunol 1998 Nov;59(11):700-12

43. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL Jr, **Cerundolo V**, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A 1998 Oct 27;95(22):13120-4

42. Ogg GS, Rod Dunbar P, Romero P, Chen JL, **Cerundolo V**. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998 Sep 21;188(6):1203-8

41. Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, **Cerundolo V**. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998 Mar 26;8(7):413-6

40. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, **Cerundolo V**, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998 Mar 27;279(5359):2103-6

39. Springer S, Doring K, Skipper JC, Townsend AR, **Cerundolo V**. Fast association rates suggest a conformational change in the MHC class I molecule H-2Db upon peptide binding. Biochemistry 1998 Mar 3;37(9):3001-12

38. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, **Cerundolo V**, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998 Apr 1;160(7):3096-100

37. Braud VM, McMichael AJ, **Cerundolo V**. Differential processing of influenza nucleoprotein in human and mouse cells. Eur J Immunol 1998 Feb;28(2):625-35

36. Teisserenc H, Schmitt W, Blake N, Dunbar R, Gadola S, Gross WL, Exley A, **Cerundolo V**. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett 1997 Jun 1;57(1-3):183-7

35. **Cerundolo V**, Benham A, Braud V, Mukherjee S, Gould K, Macino B, Neefjes J, Townsend A. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol 1997 Jan;27(1):336-41

34. **Cerundolo V**, Braud V. Cell Biology of MHC class I molecules. Ed. McMichael, Browning. ß-Bios Publishing Company, 1997

33. Tomiyama H, Takamiya Y, Hill AB, **Cerundolo V**, Kelly A, Egawa K, Trowsdale J, Takiguchi M. Isolation of a human allo-peptide presented by HLA-B51 molecules. Int Immunol 1995 Jun;7(6):905-9

32. Elliott T, Willis A, **Cerundolo V**, Townsend A. Processing of major istocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med 1995 Apr 1;181(4):1481-91

31. **Cerundolo V**, Kelly A, Elliott T, Trowsdale J, Townsend A. Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. Eur J Immunol 1995 Feb;25(2):554-62

30. Elvin J, Potter C, Elliott T, **Cerundolo V**, Townsend A. A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J Immunol Methods 1993 Feb 3;158(2):161-71

29. **Cerundolo V**. Antigen processing and presentation. The role of the endoplasmic reticulum. Subcell Biochem 1993;21:209-28

28. Elliott T, **Cerundolo V**, Townsend A Short peptides assist the folding of free class I heavy chains in solution. Eur J Immunol 1992 Dec;22(12):3121-5

27. **Cerundolo V**, Elliott T, Townsend A. The kinetics of association of peptides with MHC class I molecules. Progress in Immunology VIII Springer-Verlag 1992 175-7

26. **Cerundolo V**, Elliott T, Elvin J, Bastin J, Townsend A. Association of the human invariant chain with H-2 Db class I molecules. Eur J Immunol 1992 Sep;22(9):2243-8

25. Elliott T, Elvin J, **Cerundolo V**, Allen H, Townsend A. Structural requirements for the peptide-induced conformational change of free major histocompatibility complex class I heavy chains. Eur J Immunol 1992 Aug;22(8):2085-91

24. van Binnendijk RS, van Baalen CA, Poelen MC, de Vries P, Boes J, **Cerundolo V**, Osterhaus AD, UytdeHaag FG. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J Exp Med 1992 Jul 1;176(1):119-28

23. Spies T, **Cerundolo V**, Colonna M, Cresswell P, Townsend A, DeMars R. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature 1992 Feb 13;355(6361):644-6

22. Zanovello P, Rosato A, Bronte V, Mandruzzato S, **Cerundolo V**, Collavo D. Antitumour

efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. <u>Cancer Immunol Immunother</u> 1992;35(1):27-32

21. Elvin J, **Cerundolo V**, Elliott T, Townsend A. Analysis of HIV-1 gag peptides with a quantitative peptide-dependent class I assembly. <u>Cytotoxic T cells in HIV and other retroviral infections</u>. Ed. P. Racz, N. Letvin, J. Gluckman. Kager 1992; 255-60

20. Elvin J, **Cerundolo V**, Elliott T, Townsend A. A quantitative assay of peptide-dependent class I assembly. <u>Eur J Immunol</u> 1991 Sep;21(9):2025-31

19. **Cerundolo V**, Elliott T, Elvin J, Bastin J, Rammensee HG, Townsend A. The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. <u>Eur J Immunol</u> 1991 Sep; 21(9):2069-75

18. Elliott T, **Cerundolo V**, Elvin J, Townsend A. Peptide-induced conformational change of the class I heavy chain. <u>Nature</u> 1991 May 30;351(6325):402-6

17. **Cerundolo V**, Tse AG, Salter RD, Parham P, Townsend A. CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68.1. <u>Proc R Soc Lond B Biol Sci</u> 1991 May 22;244(1310):169-77

16. Zanovello P, Rosato A, Bronte V, **Cerundolo V**, Collavo D. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins. <u>Ann Ist Super Sanita</u> 1991;27(1):91-5

15. Elliott TJ, **Cerundolo V**, Ohlen C, Ljunggren HG, Karre K, Townsend A. Antigen presentation and the association of class-I molecules. <u>Acta Biol Hung</u> 1991;42(1-3):213-29

14. Elliott T, Townsend A, **Cerundolo V**. Antigen presentation. Naturally processed peptides. <u>Nature</u> 1990 Nov 15;348(6298):195-7

13. Townsend A, Elliott T, **Cerundolo V**, Foster L, Barber B, Tse A. Assembly of MHC class I molecules analyzed in vitro. <u>Cell</u> 1990 Jul 27;62(2):285-95

12. **Cerundolo V**, Alexander J, Anderson K, Lamb C, Cresswell P, McMichael A, Gotch F, Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. <u>Nature</u> 1990 May 31;345(6274):449-52

11. Zanovello P, **Cerundolo V**, Bronte V, Giunta M, Panozzo M, Biasi G, Collavo D. Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. <u>Cell Immunol</u> 1989 Sep;122(2):450-60

10. Zanovello P, Rosato A, Bronte V, **Cerundolo V**, Treves S, Di Virgilio F, Pozzan T, Biasi G, Collavo D. Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. <u>J Exp Med</u> 1989 Sep 1;170(3):665-77

9. Treves S, Di Virgilio F, **Cerundolo V**, Zanovello P, Collavo D, Pozzan T. Calcium and inositolphosphates in the activation of T cell-mediated cytotoxicity. <u>J Exp Med</u> 1987 Jul 1;166(1):33-42

8. **Cerundolo V**, Zanovello P, McIntosh D, Fabbris R, Davies AJ, Collavo D. Temporary inhibition of Moloney-murine sarcoma virus (M-MSV) induced-tumours by adoptive transfer of ricin-treated T-lymphocytes. <u>Br J Cancer</u> 1987 Apr;55(4):413-9

7. **Cerundolo V**, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone. <u>Eur J Immunol</u> 1987 Feb;17(2):173-8

6. Collavo D, Ronchese F, **Cerundolo V**, Zanovello P. Effetto della ciclofosfamide sui meccanismi di controllo immunologico. <u>Gli agenti alchilanti</u> Ed. CLEUP 1985 175-81

5. **Cerundolo V**, Engers HD, Zanovello P, Ronchese F, Collavo D. Protection from virus induced tumors by the injection of virus specific cytotoxic T lymphocyte clones. <u>New Trends in Experimental Hematology.</u> Ed. Peschle and Rizzoli 1985 271-4

4. **Cerundolo V**, Zanovello P, Ronchese F, Giunta M, Collavo D. Valutazione dell'effetto della Ciclofosfamide sui precursori delle cellule con attivita' citotossica. <u>Therapeutika</u> 1985 3:187-9

3. Ronchese F, Collavo D, Zanovello P, Cerundolo V, Biasi G. Reversibility of lymphokine-induced NK-like activity in virus-specific cytotoxic T-lymphocyte clones. <u>Immunology</u> 1985 Feb;54(2):265-74

2. Collavo D, Ronchese F, Zanovello P, De Rossi A, **Cerundolo V**. Pathogenesis of murine virus-induced T cell lymphomas. <u>Frontiers in Experimental Hematology</u>. Ed. Torelli, Bagnara, Brunelli 1984 196-9

1. Collavo D, Ronchese F, Zanovello P, **Cerundolo V**, Biasi G. Reduction in precursors of cytotoxic T lymphocytes and of cells with natural killer-like activity in spleens of cyclophosphamide-treated mice. <u>Int J Immunopharmacol</u> 1984;6(5):529-34

```
                     Alignment Mouse and Human MHC molecules
#######################################
# Program:  needle
# Rundate:  Thu Jul 12 12:21:38 2007
# Align_format: srspair
# Report_file: /ebi/extserv/old-work/needle-20070712-12213313046124.output
#######################################

#=======================================
#
# Aligned_sequences: 2
# 1: EMBOSS_001 AAA53203 Mouse MHC
# 2: EMBOSS_002 AAA76608 Human MHC
# Matrix: EBLOSUM62
# Gap_penalty: 10.0
# Extend_penalty: 0.5
#
# Length: 381
# Identity:     239/381 (62.7%)
# Similarity:   275/381 (72.2%)
# Gaps:          28/381 ( 7.3%)
# Score: 1218.5
#
#
#=======================================

EMBOSS_001         1     mapcmlllllaaalaptqtragphslryfhtavsrpglgkprfisvg    47
                         |||..|:|||:.|||.|||.||.||:|||.|:|||||.|:||||:||
EMBOSS_002         1 mavmaprtlvlllsgalaltqtwagshsmryfftsvsrpgrgeprfiavg    50

EMBOSS_001        48 yvddtqfvrfdsdaenpryeprvrwmeqvepeywerntqiakgneqifrv    97
                     ||||||||||||||||.:.|.|||..|:||..|||||:...|:..|.:.|..||
EMBOSS_002        51 yvddtqfvrfdsdaasqrmeprapwieqegpeywdgetrkvkahsqthrv   100

EMBOSS_001        98 slrtalryynqsaggshtfqrmygcevgsdwrllrgyeqyaydgcdyial   147
                     .|.|...|||||..||||.||||||:|||||.||||.||||||.||||
EMBOSS_002       101 dlgtlrgyynqseagshtvqrmygcdvgsdwrflrgyhqyaydgkdyial   150

EMBOSS_001       148 nedlktwtaadmaalitkhkweqagdaerdraylegtcvewlrrylqlgn   197
                     .|||::||||||||..||||||.|..||:.||||||||||||||||:.|.
EMBOSS_002       151 kedlrswtaadmaaqttkhkweaahvaeqlraylegtcvewlrrylengk   200

EMBOSS_001       198 atlprtdspkahvtrhsrpedkvtlrcwalgfypaditltwqlngeeltq   247
                     .||.|||:||.|:|.|:...:::|||||||.|||||.||||:||||||.:||:.||
EMBOSS_002       201 etlqrtdapkthmthhavsdheatlrcwalsfypaeitltwqrdgedqtq   250

EMBOSS_001       248 dmelvetrpagdgtfqkwasvvvplgkeqyytchvyhqglpepltlrwep   297
                     |.||||||||||||||||||.|:||.||||||.|:|||:|||||||||
EMBOSS_002       251 dtelvetrpagdgtfqkwaavvvpsgqeqrytchvqheglpkpltlrwep   300

EMBOSS_001       298 pps-tvsntviiavlvvlgaaivtgavvafvmkmrrrntaflltggkggd   346
                     ...  |:....|||.||:.| |::||||||.||..|:.:..      |||.
EMBOSS_002       301 ssqptipivgiiaglvlfg-avitgavvaavmwrrkssdr------kggs   343

EMBOSS_001       347 yalapgs---qtsdlslpdckvmvhdphsla        374
                     |:.|..|       |.||:||
EMBOSS_002       344 ysqaassdsaqgsdvsl                   360


#---------------------------------------
#---------------------------------------
```

Formatting antibody fragments to mediate specific therapeutic functions.

Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD.
Celltech R+D Ltd., 216 Bath Road, Slough, Berkshire SL1 4EN, UK.
neil.weir@slh.celltechgroup.com

Monoclonal antibodies are increasingly being used as therapeutic agents in a wide range of indications, including oncology, inflammation and infectious disease. In most cases the basis of the therapeutic function is the high degree of specificity and affinity the antibody-based drug has for its target antigen. However, the mechanism of action (MOA), the way the drug takes advantage of this specificity to mediate a therapeutic effect, varies considerably from drug to drug. Three basic potential categories of MOAs exist: antagonists, agonists and specific delivery mechanisms to target an active function to a particular cell type. The latter functions include selective cell killing, based on Fc-mediated events, recruitment of effector cells, and drug or radioisotope delivery. The majority of these mechanisms are not necessarily optimally mediated by an IgG structure; clearly, in the case of antibody-dependent cellular cytotoxicity or complement-mediated lysis, Fc is required. However, Fab fragments (the fragment comprising one antigen-binding arm of the Y-shaped IgG molecule) can be formatted to mediate most mechanisms and have the advantage that valency and half-life can be controlled to simplify the drug and address only the mechanism required. Moreover, Fab fragments can be produced in microbial expression systems which address manufacturing issues such as scale of supply and cost of goods.

Wendy L. Tamminen^{ΔO},
David Wraith⁺ and
Brian H. Barber^Δ

Department of Immunology, University
of Toronto^Δ, Toronto and Immunology
Division, National Institute for Medical
Research⁺, London

Searching for MHC-restricted anti-viral antibodies: antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells*

An attempt has been made to generate monoclonal antibodies which recognize the same target structures on influenza-infected cells as those seen by cytotoxic T lymphocyte (CTL) receptors. Such antibodies, if they mimicked the T cell receptor specificity, would be expected to be both virus specific and restricted in their binding by the major histocompatibility complex (MHC) antigens. Approximately 200 hybridomas from C57BL/6 (H-2^b) mice primed and boosted with influenza virus (X-31)-infected EL4 (a C57BL/6 T cell lymphoma) were screened for reactivity on infected and uninfected cells of different MHC haplotypes. Of the 10 hybridoma antibodies which were identified as being reactive with X-31-infected EL4, but not uninfected EL4, all reacted equally well with X-31-infected cells of H-2^b, H-2^d and H-2^k haplotypes, indicating a lack of MHC restriction in their recognition of the infected cells. Unexpectedly, 7 of the 10 monoclonal antibodies were found to react specifically with the purified influenza virus nucleoprotein (NP), a predominant viral antigen in CTL recognition of infected cells. Fluorescence-activated flow cytometry confirmed that these antibodies were able to recognize NP serological determinants on the surface of viable, infected cells, but the anti-NP antibodies were unable to block the lytic activity of an NP-specific CTL clone.

1 Introduction

Virus-specific cytotoxic T lymphocytes (CTL) are known to recognize foreign determinants on infected cells in the context of class I major histocompatibility complex (MHC) gene products [1]. Although considerable progress has recently been made in terms of defining the nature of the T cell antigen receptor (reviewed in [2]), much uncertainty remains with respect to the nature of the target structures seen by CTL on the surface of virus-infected cells. The study of CTL target structures and their formation would be greatly facilitated by the availability of monoclonal antibodies (mAB) recognizing structural determinants which either overlap with, or are identical to, those seen by the CTL antigen receptors. Such antibodies would be analogous to soluble T cell receptors, and could provide an important set of immunological tools for defining the nature of CTL target structures.

Wylie et al. [3] previously reported that, using a splenic fragment culture assay, the majority of responding primary B cell clones produced in mice challenged with influenza virus-infected cells secreted antibodies which were MHC restricted in their binding to influenza-infected cells. The majority of

these were found to recognize the influenza virus hemagglutinin (HA) in the context of class I MHC determinants. Encouraged by this finding, we undertook to determine if conventional mAb could be generated which would recognize influenza virus determinants in the context of MHC antigens. Spleen cells from mice challenged 2–4 times with viable, influenza A-type virus-infected syngeneic cells were used to produce antibody-secreting hybridoma clones. Of the 10 hybridoma clones specific for influenza virus-infected cells characterized in this study, none produced antibody dependent on the haplotype of the infected target cell for binding. Surprisingly, 7 of the 10 mAb were found to be specific for the influenza nucleoprotein (NP), the component previously identified as being immunodominant with respect to influenza virus-specific CTL [4]. Although the NP-specific mAb antibodies were able to detect NP serological determinants on the surface of viable infected cells, they were unable to block lysis of influenza-infected cells by an NP-specific CTL clone.

2 Materials and methods

2.1 Viruses

All influenza viruses were grown from seed stock generously provided by J. J. Skehel (WHO Influenza Reference Center, Mill Hill, GB). Virus was grown at 34 °C in the allantoic cavity of 10-day-old embryonated chicken eggs. Infectious allantoic fluid was isolated, titred for hemagglutination activity against chicken red blood cells and stored at −70 °C. The following strains of influenza virus were used: natural isolates; A/PR/8/34(H1N1), A/Hong Kong/1/68(H3N2), A/Texas/1/77(H3N2) and B/Hong Kong/8/73 and recombinant viruses isolated from mixed infections with A/PR/8/34 and post-1968 H3N2 viruses; X-31, X-47, E61-24-H16 and E61-13-H17. The genotypes of the recombinants are shown in Table 1 as previously described [5, 6].

[I 5929]

Abbreviations: MHC: Major histocompatibility complex NP: Nucleoprotein HA: Hemagglutinin NA: Neuraminidase CTL: Cytotoxic T lymphocyte(s) PBS: Phosphate-buffered saline ELISA: Enzyme-linked immunosorbent assay RIA: Radioimmunoassay HAT: Hypoxanthine aminopterin thymidine PEG: Polyethylene glycol mAb: Monoclonal antibody(ies) BSA: Bovine serum albumin

Table 1. Genotypes of recombinant viruses[a]

Virus	PB1	PA	PB2	HA	NA	NP	M	NS
X-31					o	x	x	x
X-47	o			o	o	o	x	x
H17	x			o	o	o	x	x
H16	o			o	o	x	x	o

a) x denotes a gene derived from A/PR/8/34; o denotes a gene derived from post-1968 H3N2 viruses; PB1, PA, PB2, viral polymerases; M, matrix protein; NS, nonstructural proteins.

2.2 Cell lines

The following cell lines, obtained from the American Type Culture Collection (Rockville, MD), were used: EL4 (H-2^b, T cell lymphoma) [7], P815 (H-2^d, mastocytoma) [8], BW5147.G.1.4. (H-2^k, T cell lymphoma) [7] and Sp2/0 H-2^d, H chain$^-$, L chain$^-$ myeloma) [9]. Cell lines were maintained in culture in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS), 2 mM penicillin/streptomycin, 2 mM L-glutamine and, in the case of Sp2/0, 2 mM sodium pyruvate. All cultures were kept at 37 °C in a humidified atmosphere with 5% CO_2.

2.3 mAb

The antibody-producing lines HB-11 (20-8-4S, anti-K^{b}D^b) [10], HB-20 (3-83-P, anti-H-2K^{k}D^k) [11] and HB-65 (H16-L-10-HRS, anti-FluA NP) [12] were obtained from ATCC, and Y3 (anti-H-2K^b) was kindly provided by C. Janeway. The corresponding mAb were utilized as culture supernatants. HC-3, a monoclonal anti-HA (H3) ascites fluid, was generously supplied by J. J.Skehel. Anti-phosphorylcholine (anti-PC) antibody, PC28/3-7, was obtained from M. Shulman.

2.4 Influenza virus infection of murine tumor cells

Tumor cells were harvested and washed twice with serum-free medium before being resuspended with 200–500 μl of infectious allantoic fluid (500 hemagglutinating units, HAU/1 × 10^7 cells) and an equal volume of serum-free medium. Incubation was for 1 h (37 °C, 7% CO_2) with agitation every 15 min. Cells were then washed twice with RPMI 1640 containing 10% FBS and subsequently placed in culture flasks at approximately 1 × 10^6 cell/ml in RPMI 1640/2 mM penicillin-streptomycin/10% FBS/2 mM L-glutamine. Flasks were returned to the incubator for 5–12 h to allow for expression of viral proteins after which cells were harvested for use.

2.5 Immunization of mice with syngeneic infected tumor cells

X-31-infected EL4 tumor cells were washed and resuspended in phosphate-buffered saline (PBS) at 1 × 10^7 cells/ml. C57BL/6J (H-2^b) mice, 20–36 weeks old, obtained from Jackson Laboratories (Bar Harbor, ME), were challenged with 1 × 10^7 infected cells by i.p. injection. Mice were re-challenged once or twice in the same way with 3–4 weeks spacing between injections. At 3–8 weeks after the final immunization, the

mice were given an i.p. or i.v. boost identical to the previous immunization(s) and the immune spleen cells were used 3–4 days later for fusion.

2.6 Fusion of immune spleen cells with Sp2/0

The fusion protocol was adapted from the procedure suggested by De St. Groth and Scheidegger [13]. Antibiotics (2 mM penicillin/streptomycin) were included in all media and buffers used. In general, spleens from 2 immune mice were pooled. The fusion parter, Sp2/0, was harvested from culture at no greater than 3 × 10^5–4 × 10^5 cells/ml, washed and resuspended in RPMI 1640/10 mM HEPES (HEPES 1640). Equal numbers of immune spleen cells and Sp2/0 (4 × 10^7–5 × 10^7 each) were combined, washed once with HEPES 1640, and fused with 1.0 ml of polyethylene glycol (PEG 4000, Merck, Darmstadt, FRG, 50% in HEPES 1640) added dropwise over 1 min. After agitation at 37 °C for 90 s the fusion was stopped by addition of 20 ml HEPES 1640. An equal volume of RPMI 1640/10% FBS was added and the cells were left to stand at room temperature for 5 min before suspending and pelleting. Cells were then resuspended to 5 × 10^6/ml in RPMI 1640/10% FBS/HAT/L-glutamine/sodium pyruvate (HAT medium). Cells (2.5 × 10^5) were then seeded into each well of 24-well plates previously prepared with a feeder layer of C57BL/6J spleen cells. The plates were placed in a humidified incubator with 5% CO_2.

On day 7 after the fusion, 1 ml of the HAT medium was added to each well, and on days 10, 12 and 14, wells were fed with fresh HAT medium. Between days 14 and 21 wells were fed with HT medium (i.e. HAT medium lacking aminopterin) and thereafter maintained on RPMI 1640 containing 10% FBS, L-glutamine, sodium pyruvate and antibiotics. Supernatants were collected for testing when wells were half-confluent and then stored at −20 °C. Representative positive wells were later selected for cloning by limiting dilution. In some instances, clones were expanded for larger scale antibody production. Antibodies were purified by protein A-Sepharose (Pharmacia, Uppsala, Sweden) affinity chromatography (according to Ey et al. [14]) and concentrated to > 1 mg/ml by pressure ultrafiltration (Amicon, Lexington, MA). Purified mAb were stored at 4 °C in the presence of 10 mM sodium azide.

2.7 Preparation of antigen plates for enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA)

Three types of antigen targets were prepared using flexible, round-bottom, 96-well polyvinyl chloride microtiter plates (Linbro, New Haven, CT).

(a) Cellular targets. These were prepared using modifications of methods described in the literature [15, 16]. Infected or uninfected tumor cells were harvested from culture, washed three times in PBS and resupended at 1 × 10^6 cells/ml. A volume of 100 μl was dispensed into each well of target plates which had been pre-treated with poly-L-lysine (0.05 mg/ml: 50 μl/well) for 45 min at room temperature. The plates were then centrifuged at 400 × g for 7 min at room temperature (RT) and 100 μl of 0.2% glutaraldehyde was added for 5 min at RT. The plates were then flicked and washed three times with PBS. Nonspecific binding sites were blocked by filling the wells with 0.5% bovine serum albumin (BSA)/0.02% sodium

azide/PBS (blocking buffer) and incubating for 1 h at RT. The plates were either used immediately or stored at 4°C for up to several months without removal of the blocking buffer.

(b) *Whole virus targets*. Infectious allantoic fluid was diluted to 20 HAU/25 µl with PBS; 25 µl (20 HAU) of the viral solution was dispensed per well and the plates were left to air-dry overnight. The plates were then incubated with blocking buffer and stored as for the cellular targets. As a control, plates were also prepared using uninfected (normal) allantoic fluid.

(c) *Purified viral protein targets*. Plates were prepared with 0.4 µg/well of NP purified from A/X-31 [17]. These wells were incubated with blocking buffer for 1 h before use. The bromelain fragment of the HA (BHA) from X-31 was kindly supplied by J. J. Skehel. Purified neuraminidase (NA) from A/Jap/305/57 (H2N2) was obtained commercially (Calbiochem, Los Angeles, CA). The BHA and NA were diluted in PBS to concentrations of 5–625 µg/ml and 50 µl was dispensed per well. After incubating for 1 h at RT, plates were flicked, blocked as above and stored as for the cellular targets.

2.8 ELISA and RIA

Each mAb of interest was diluted to an appropriate concentration with blocking buffer. The assay wells were flicked to remove the blocking buffer and blotted dry. Fifty µl of sample antibody was added per assay well and incubated for 1–2 h at RT. The antibody was then flicked off and the wells were washed three times with PBS. If performing an ELISA, 100 µl of urease-conjugated rabbit anti-mouse Ig [µ and γ chain-specific antibody (Allelix, Toronto, Canada) 1:500 dilution] was added to the wells and allowed to incubate for 45 min at 34°C. After flicking off the antibody-enzyme conjugate, the wells were washed three times in PBS followed by three washes with deionized water. One hundred µl of urease substrate solution (Allelix) was then added to each well. Color development after 15–20 min was determined by absorbance at 595 nm. In performing a RIA, instead of adding the urease-conjugate as the second antibody, 50 µl of an ^{125}I-labeled protein A (Amersham Int., Bucks, GB), prod. n. IM.112) solution containing 50000–60000 cpm/50 µl was added to each well and incubated for 1–2 h at RT. Unbound ^{125}I-protein A was removed by washing three times with PBS. The wells were dried, cut out and counted in a γ-counter.

2.9 Flow cytometry of influenza-virus infected cells

X-31-infected EL4 tumor cells were harvested and washed two times in PBS. Cells were distributed into 10 ml round-bottom centrifuge tubes at 1.2 × 10⁶ cells/tube and washed once more in RPMI 1640/0.1% BSA/0.1% sodium azide (binding buffer), spinning at 400 × g for 8 min at RT. The supernatant was removed and the pellet gently resuspended in 100 µl each of ice-cold binding buffer and sample antibody. The tubes were incubated on ice for 1 h, with agitation every 10 min. After washing twice at 4°C with binding buffer, the pellet was resuspended with 100 µl of a 1:20 dilution of fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG antibody (Cappel Laboratories, Cochranville, PA). The tubes were incubated on ice for 30 min, agitating every 10 min. The cells were then washed once in binding buffer, once in PBS, and resuspended in 1 ml of PBS. Immediately before analysis on the EPIC V flow cytometer (Coulter, Harpenden, GB), each sample was mixed with 1/10 volume of propidium iodide (1 mg/ml). Pro-

pidium iodide was added to stain the DNA of nonviable cells, allowing their exclusion from analysis [18]. For purposes of comparison, mean peak fluorescence intensities were converted from logarithmic to relative fluorescence intensities (RFI) by a standard arithmetic relationship.

2.10 Generation and assay of an anti-influenza CTL

The A-type influenza-specific CTL clone, B4, was established from X-31-infected C57BL/6 mice using the protocol described by Townsend and Skehel [19]. The specificity of the clone was established using a standard ^{51}Cr-release assay for cell-mediated cytotoxicity with different target cells infected with a series of recombinant influenza virus strains [20]. When the mAb were tested for their ability to inhibit the lytic activity of B4, target cells were incubated for 30 min with a 1/2 dilution of B4, the mAb-containing culture supernatants before assay, and a 1/4 dilution of the culture supernatant was maintained throughout the 4-h assay period.

3 Results

3.1 Identification of hybridomas reactive with the infected EL4 cell surface

Hybridoma culture wells containing immunogen-specific antibody were screened by ELISA for their ability to react with X-31-infected EL4 (EL4 + X-31), and failure to react with uninfected EL4 cells. Of 189 clones screened, 10 were identified with this specificity. Under the limiting dilution conditions of the initial HAT selection step, the percentage of wells positive for growth in each fusion was less than 50%, while the percentage of wells reactive with infected but not uninfected EL4 was less than 3%. These frequencies strongly suggest that the virus-specific antibodies from any of the 10 positive wells are very likely to be monoclonal. This conclusion was further supported when 4 of the 10 positive wells were later subcloned and found to retain their original specificity (data not shown).

3.2 mAb reactivity with infected cells of different haplotypes

To test for involvement of class I MHC antigens in the formation of infection-specific serological determinants, the antibodies were screened by RIA for differential reactivity on X-31-infected tumor cells of the b, d and k haplotypes. If any of the hybridoma antibodies were specific for influenza antigens in the context of self-MHC antigens, they would be expected to react only with X-31-infected target cells of the b haplotype, since the immunogen and responding host were of this haplotype. Using a comparative binding assay, possible differential reactivity of a given hybridoma with infected cells of different haplotypes could be masked by the presence in the same fusion well of a hybridoma strictly specific for an influenza antigen, since antibody of such specificity would bind to X-31-infected targets of all haplotypes. It was for this reason that we incorporated a cloning step into the initial hybridoma selection procedure after fusion.

Using the control antibodies HC-3 and HB-65 specific for HA and NP, respectively, it was found that, under conditions of antibody saturation, there was an inherent inequality among the different cell types in terms of their expression of HA and

NP. This made it impossible to compare directly the binding data for the cells of different haplotypes. P815 (H-2^d) showed low levels of detectable viral proteins relative to EL4 (H-2^b) and BW5147 (H-2^k). The surface HA expression with another k haplotype T cell lymphoma, RDM-4 was also lower than that with EL4 or BW5147, indicating that the reduced level of expression seen with P815 is not unique to the d haplotype (data not shown). The reason for this variation among cell types is not known, but might be due to differences in their inherent susceptibility to infection or different rates of viral protein synthesis. In order to permit a comparison of antibody binding on cells of different haplotype, the control levels of anti-HA and anti-NP binding at saturation were taken as an indicator of the availability of viral determinants on the various infected cell types. Assay results were then normalized by expressing the binding of each sample antibody as a fraction of the binding of either the anti-HA or anti-NP control. The results, both absolute and relative, are summarized in Table 2. As an example of how important this normalization turned out to be, the absolute results for EX9 indicate that binding on

infected EL4 and BW5147 cells was roughly 5–6 times greater than binding on infected P815, which might be interpreted as a true difference in affinity of the antibody for the different targets. However, once the results are normalized to account for differences in the amounts of viral determinants available, the antibody is seen to have little preference for one target haplotype over another. Of the 10 antibodies tested, none showed significant differences in binding as a function of infected-cell haplotype, indicating a lack of involvement of the class I molecules in formation of the serological determinants recognizing by the antibodies.

3.3 mAb reactivity with different influenza-virus-infected targets

The lack of MHC restriction of the 10 antibodies suggested that they were likely specific for the influenza antigens alone. On the basis of previously reported B cell responses to both influenza virus and influenza-infected cells [3, 21, 22], we expected that the viral glycoproteins would be the dominant antigens recognized by the infected cell-specific antibodies. In order to test for such glycoprotein specificity, the reactivity of the antibodies with X-31 and PR8-infected EL4 cells was compared. The immunizing recombinant strain, X-31, derives its HA and NA genes from A/HK/1/68(H3N2) and all other genes from A/PR/8/34(H1N1) as shown in Table 1. Since H3 and N2 are serologically non-cross-reactive with H1 and N1, respectively [23], an antibody-recognizing glycoprotein determinants should react with X-31-, but not PR8-infected EL4. On the other hand, if nonglycosylated viral proteins were involved in determinant formation, the antibody specific for these epitopes would react with both X-31- and PR8-infected EL4. Representative RIA results of the reactivity of the antibodies against both X-31- and PR8-infected EL4 are shown in Table 3. Surprisingly, it was found that 8 of the 10 antibodies were reactive with both infected targets, suggesting that the majority of the antibodies recognized determinants formed by the nonglycosylated viral components, and not the glycoproteins. Although it is possible that there might exist serological

Table 2. mAb reactivity with infected cells of different haplotype

mAb		Infected cell target (cpm bound)[a]		
		EL4 + X-31 (H-2^b)	P815 + X-31 (H-2^d)	BW5147 + X-31 (H-2^k)
HC-3	(HA)	19295	3432	10773
HB-65	(NP)		1568	8007
EX1			1730	
	ratio		0.50	
			1.10	
			2234	
			1588	
			2553	
			0	
EX5			3312	45933
	ratio	0.72	0.96	0.80
	ratio		2.11	1.85
EX6		21030	3915	20512
	ratio to HA	1.49	1.14	2.04
	ratio to NP	2.22	2.50	2.38
EX7		1244	548	3433
	ratio to HA	0.18	0.16	0.17
	ratio to NP	0.40	0.35	0.40
EX8		9652	2254	9503
	ratio to HA	0.50	0.66	0.48
	ratio to NP	1.10	1.44	1.10
EX9		7691	1414	9187
	ratio to HA	0.40	0.41	0.46
	ratio to NP	0.89	0.90	1.07
EX10		8057	2542	9425
	ratio to HA	0.42	0.74	0.48
	ratio to NP	0.93	1.62	1.10

a) Values represent the mean of duplicates unless otherwise noted.
b) Uninfected target cells had background levels of 200–400 cpm; see Table 3.
c) Single point assay.

Table 3. mAb reactivity with different influenza virus-infected targets

mAb		Infected cell target (cpm bound)[a]		
		EL4 (H3N2)	EL4 + X-31 (H3N2)	EL4 + PR8 (H1N1)
HC-3 (anti-H3)		254	23097	207
HB-65 (anti-NP)		198	15352	5901
HB-20 (anti-HA SD)		788	522	352
EX1		422	15697	6791
EX2		446	14	7981
EX3		242	18	8544
EX4		202	22	2128
EX5		125	7284	170
EX6		118	2432	69
EX7		438	14463	6783
EX8		199	9878	5374
EX9		182	12384	5240
EX10		412	9154	4244

a) All values represent the mean of duplicates.
b) In this and subsequent tables responses considered significantly above background levels are underlined.

(EX3, 7, 8 and 9) cross-reacted on all four A-type strains tested, although the binding of EX8 and EX9 to HK was relatively weak. These findings indicate that this group of anti-NP monoclonals recognize a serological determinant common to both the PR8 and HK-derived NP.

The NP of influenza virus has recently been divided into two subgroups based on the ability of influenza-stimulated CTL to differentiate between the NP from these groups. One subgroup consists of the isolates from 1934–1943 (A/PR/8/34-related) while those from 1946–1979 (A/HK/8/68-related) form the second subgroup [20]. It was thus interesting that EX1 and EX2 could discriminate between targets in the same way expected for a subtype-specific CTL, reacting only with the pre-1943 NP of PR8 and not with the HK-related NP of the post-1943 isolates, HK and Texas.

3.6 Serological detection of NP determinants on viable, influenza-infected EL4 cells

It was necessary to consider the possibility that the NP detected in the RIA with fixed target cells was not expressed on the cell surface, but rather only available in the cytoplasm of infected cells rendered permeable by the glutaraldehyde fixation. To determine whether or not NP determinants were present on the surface of infected cells, affinity-purified anti-NP mAb were used to assess reactivity with intact X-31-infected EL4 cells using a fluorescence-activated cell sorter.

Figure 1. Fluorescence analysis of cell surface antigens on A/X-31-infected EL4 tumor cells. Distribution of surface antigens detected with (A) anti-phosphorylcholine (nonspecific binding control); (B) EX2 (subtype-specific anti-NP); (C) EX8 (A-type cross-reactive anti-NP); (D) HB-11 (anti-H-2K^{b}D^b); (E) EX6 (anti-HA); (F) HB-65 (anti-NP control).

Fig. 1 depicts the results of this experiment. Panel A shows that a low level of background fluorescence (5–6% positive cells) was obtained with a control antibody. Under conditions of antibody saturation, the subtype-specific anti-NP antibody, EX2 (Fig. 1B), stained 90–95% of the infected cell population, whereas the A-type cross-reactive anti-NP antibody, EX8, stained about 50% of the cells. Interestingly, HB-65, the established positive anti-NP control, which is A-type cross-reactive like EX8, had a fluorescence profile (Fig. 1F) almost identical to that of EX8 (Fig. 1C). Although the reason for the difference in distribution of cell surface NP determinants detected using different anti-NP antibodies is not known, the findings suggest a correlation between determinant distribution and subtype specificity. The anti-HA antibody, EX6 (Fig. 1E), and an anti-class I histocompatibility antigen control antibody, HB-11 (Fig. 1D), labeled 99% and 100% of the infected cells, respectively. Conversion of the mean fluorescence intensities from the logarithmic scale of Fig. 1 to relative fluorescence intensities indicated that the amount of cell surface NP detected with either of the anti-NP antibodies was approximately 10% of HA on the cell surface and 17% the amount of class I determinants detected. The broad peak observed with the anti-HA antibody (Fig. 1E) reflected considerable heterogeneity in the number of HA molecules expressed on different infected cells. In contrast, the population was relatively homogeneous in terms of cell surface expression of NP and class I determinants, as indicated by the relatively narrow distribution of fluorescent cells labeled by these antibodies.

3.7 Can the NP-specific antibodies block an influenza-specific CTL clone which recognizes the A/PR/8/34 NP?

The reactivity profile of B4 (a C57BL/6-derived influenza A-type specific CTL clone) is depicted in Table 7. B4 can recognize and lyse PR8-infected peritoneal exudate cells from B10.HTG (K^{d}D^d) mice, but not from B10.A(5R) (K^{b}D^d) mice, indicating that the clone is restricted in its recognition by H-2D^b. A/X-31 is a recombinant influenza virus which possesses the HA and NA genes of the 1968 A/HK strain in association with the internal structural genes of the 1934 PR8 strain. The observation that B4 was able to lyse PR8- and X-31-infected cells, but not HK-infected cells, indicated its specific-

Table 7. Specificity of anti-influenza CTL clone C57.B1.6 B4

Cell origin	Target	% Lysis
		24
		2
		-3
		66
		0
		67
		2
EL4 (K^b)		1
EL4 (K^b)		38
EL4 (K^b)	A/X-31 + EX2	34
EL4 (K^b)	A/X-31 + EX3	34

a) Target cells from these mouse strains were thioglycolate-induced peritoneal exudate cells.

ity for one of the internal virus components. Further analysis using target cells infected with additional recombinant viruses (Tables 1 and 7) mapped the internal component specificity to the NP gene.

Having established the NP specificity of the B4 clone, attempts were made to inhibit its CTL activity with two representative NP-specific mAb from those generated to X-31-infected EL4 cells. The results in Table 7 indicate that even under conditions where antibody binding to the target cells is expected to be in saturation, neither the A-type cross-reactive (EX3) nor the subtype-specific (EX2) anti-NP mAb were able to inhibit CTL activity significantly.

4 Discussion

The aim of this study was to determine whether or not hybridoma-derived mAb could be generated which would react with the cell surface determinants recognized by anti-influenza CTL clones. These antibodies, like antigen receptors on the CTL, would be expected to be both MHC restricted and virus specific [1]. The possibility that MHC-restricted antibodies could be generated is supported by a number of recent reports in the literature [3, 24–26]. In particular, the study of the B cell responses to immunization with syngeneic, influenza-infected tumor cells by Wylie and Klinman [21] indicated that approximately two thirds of the anti-viral antibodies recovered in a splenic fragment assay of a primary response were specific for determinants present on infected cells but not on purified virus. Further analysis [3] showed that 60% of these antibodies displayed a CTL-like MHC restriction, binding only to infected cells bearing class I antigens of the immunizing haplotype. Similar results have recently been reported by Froscher and Klinman [26] for mAb responses to SV-40 virus-transformed cells. We found that none of the 10 infected-cell-specific mAb generated in C57BL/6 mice after multiple injections of syngeneic, influenza-infected EL4 cells were restricted by the MHC in their recognition of the viral antigens. Our antibodies bound equally well to infected cells which were either allogeneic or syngeneic to the immunogen. In this context, it is important to note that we found a significant quantitative difference in the cell surface expression of influenza virus components among the different cell types used in this assay. If the binding results had not been normalized to the control values, a correlation between target cell haplotype and the degree of antibody binding might have been mistakenly assigned (see Table 2).

In addition to the lack of any apparent MHC restriction of antibody binding, each of the antibodies tested was able to react with the virus itself, and also with purified viral components, precluding any necessary involvement of cell surface components in antigen recognition by these antibodies. Although the analysis of 10 clones is by no means extensive, these results do suggest that the cell-surface target structures recognized by influenza-specific CTL may not be as serologically potent as previously thought. The contrasting high frequency of MHC-restricted antibodies observed by Wylie et al. [3] may be related to (a) differences in the immunization protocols which were used (e.g. primary vs. multiple boost responses), (b) the methods used to analyze monoclonal responses, or (c) the different A-type influenza viruses used to prepare the immunogens. It is clearly important to establish

whether or not the majority of anti-viral antibodies are MHC restricted, and the situation will only be clarified by a more complete analysis of the unique serological determinants created on the surface of influenza-infected cells.

Another result of this study was the unexpected finding that the majority of B cells responding to immunization with influenza-infected cells were specific for viral NP determinants. Although previous reports have indicated the presence of NP on the surface of influenza-infected cells [12, 27], only recently has its involvement in CTL recognition been established [4]. In contrast with the high frequency of anti-NP antibodies observed in this study with infected cell immunogens, the predominant antibody response to immunization with virus alone is directed towards HA and NA determinants [22]. Our results suggest that in a natural infection, cell surface NP determinants may become more important in the serological response after a period of host cell infection and expression of the viral genome. This notion is supported by the work of Gerhard et al. [22] which showed that, in their preparation of mAb from mice challenged with viable virus, a long wait between a final boost and subsequent fusion resulted in a relative rise in the frequency of mAb specific for internal components, with a corresponding decrease in frequency of HA- and NA-specific antibodies.

Although recent studies have shown that the majority of influenza-specific CTL recognize the viral NP [4], the mechanism by which the NP participates in the formation of a class I-restricted target structure seen by the CTL is still unknown. Because the intact NP molecule lacks a signal sequence and is not glycosylated, it is not expected to be found on the surface of viable, infected cells, making its involvement in the CTL recognition event somewhat of a mystery. Thus, it was of interest to determine the nature of the NP determinants recognized by the anti-NP antibodies generated in response to the challenge with infected cells. Binding studies using different viral targets showed that while 4 of the anti-NP mAb bound to the NP of both the PR8 and HK-related subtypes, only two reacted exclusively with the PR8 NP. A representative of each type was subcloned, purified and used in a flow cytometry analysis of infected EL4 cells (Fig. 1). The results confirmed that both subtype-specific and cross-reactive NP serological determinants were detectable on the surface of intact infected cells. Relative fluorescence intensities showed that the determinants on positively staining cells were present at 10% and 17% the amount of HA and class I MHC determinants, respectively. Since both class I molecules [28] and HA [29] have been estimated to be expressed on the cell surface at about 10^5 copies per cell, these results suggest a minimum of about 10^4 copies of NP, or serologically intact fragments derived from NP, on the infected cell surface. This estimate corresponds closely to that of 3×10^4 molecules per infected cell previously reported by Yewdell et al. [12] for influenza-infected P815 cells using other methods.

Given that the flow cytometry analysis indicated ten times more HA than NP on the surface of infected EL4 cells, it is even more noteworthy that the response to this immunogen was dominanted by anti-NP specificities. The results strongly suggest that NP determinants may be more immunogenic than the virus glycoproteins when expressed on the infected cell surface. It is known that passive immunization with anti-NP antibodies does not protect mice from influenza infection [30]. However, serum antibodies specific for viral antigens are able

to lyse virus-infected cells through a complement-mediated mechanism [31], so the NP-specific antibodies may play a role in promoting recovery from an established virus infection.

Surprisingly, under conditions of antibody saturation the sub-type-specific antibody, EX2, detected NP determinants on about 90% of the cells. In contrast, both our cross-reactive anti-NP antibody, EX8, and a previously isolated cross-reactive anti-NP antibody (HB65) reacted with only 50% of the same infected cell population. These results suggest that various NP determinants may have different capacities to reach the infected cell surface, or do so using different pathways. This finding may be related to the recent observation by Townsend et al. [32] that in cells transfected with the NP gene, the amino- and carboxy-terminal portions of the protein appear capable of independently reaching the point of CTL recognition.

In an attempt to determine whether or not the serological detection of NP on the surface of infected cells was in any way related to the recognition of NP determinants by CTL, we tested both the subtype-specific (EX2) and the A-type cross-reactive (EX3) anti-NP mAb for their ability to inhibit infected cell lysis mediated by the NP-specific CTL clone B4. Inasmuch as the CTL clone B4 had been shown to be specific for the PR8 NP, it was expected that the mAb EX2, which is also specific for the PR8 NP, would be the most likely to inhibit recognition and lysis. However, neither EX2 nor EX3 were effective as inhibitors of the B4 clone recognition of X-31-infected EL4 cells. Certainly the inability of anti-viral antibodies (either polyclonal or monoclonal) to block lysis by virus-specific CTL is not a unique result, as the vast majority of such attempts have failed to yield positive results [4, 33]. Possible explanations for a negative result include a spatial separation of the serological and T cell-reactive sites on the NP molecule, such that antibody binding to the NP expressed on the cell surface would be unable to interfere sterically with the MHC-restricted recognition of NP by the CTL antigen receptor. Alternatively, the serologically detected NP determinants may be on separate fragments of NP from those which are detected by the T cell receptor. Quite recently, Townsend et al. [34] reported that synthetic peptides corresponding to a defined region of the NP amino acid sequence have the ability to form the MHC-restricted target structures recognized by influenza NP-specific CTL clones. Previously these same workers reported that cells transfected with truncated NP genes could also be recognized by NP-specific CTL clones under conditions where NP serological determinants were not appreciably detectable on the surface of the transfected target cells [32]. These findings, and our inability to inhibit an NP-specific CTL clone with either the subtype-specific or cross-reactive mAb, support the notion that the serologically detectable and T cell-reactive forms of the NP molecule represent distinct entities on the infected cell surface. Determining whether the serologically detectable NP is biosynthesized by the cell on which it appears, or is acquired from neighboring infected cells by a process of adsorption, may help clarify this uncertainty. We are presently making use of the anti-NP mAb to address this question.

5 References

1 Zinkernagel, R. M. and Doherty, P. C., *Adv. Immunol.* 1979. *27:* 51.

2 Collins, M. K. L. and Owen, M. J., *Biochem. J.* 1985. *230:* 281.

3 Wylie, D. E., Sherman, L. A. and Klinman, N. R., *J. Exp. Med.* 1982. *155:* 403.

4 Townsend, A. R. M. and McMichael, A. J., *Prog. Allergy* 1985 *86:* 10.

5 Lubeck, M. D., Palese, P. and Schulman, J. L., *Virology* 1982. *95:* 269.

6 Baez, M., Palese, P. and Kilbourne, E. D., *J. Infect. Dis.* 1980. *141:* 362.

7 Ralph, P., *J. Immunol.* 1973. *110:* 1470.

8 Ralph, P., Moore, M. A. S. and Nilsson, K., *J. Exp. Med.* 1976. *143:* 1528.

9 Shulman, M. J., Wilde, C. D. and Köhler, G., *Nature* 1978. *276:* 269.

10 Ozato, K. and Sachs, D. H., *J. Immunol.* 1981. *126:* 317.

11 Ozato, K., Mayer, N. and Sachs, D. H., *J. Immunol.* 1980. *124:* 533.

12 Yewdell, J. W., Frank, E. and Gerhard, W., *J. Immunol.* 1981. *126:* 1814.

13 De St. Groth, S. F. and Scheidegger, D., *J. Immunol. Methods* 1980. *35:* 1.

14 Ey, P. L., Prowse, S. J. and Jenkin, C. R., *Immunochemistry* 1978. *15:* 429.

15 Stocker, J. W. and Heusser, C. H., *J. Immunol. Methods* 1979. *26:* 87.

16 Epstein, S. L. and Lunney, J. K., *J. Immunol. Methods* 1985. *76:* 63.

17 Wraith, D. C. and Askonas, B. A., *J. Gen. Virol.* 1985. *66:* 1327.

18 Wallen, C. A., Higashikubo, R. and RotiRoti, J. L., *Cell Tissue Kinet.* 1983. *16:* 357.

19 Townsend, A. R. M. and Skehel, J. J., *Nature* 1982. *300:* 655.

20 Townsend, A. R. M. and Skehel, J. J., *J. Exp. Med.* 1984. *160:* 552.

21 Wylie, D. E. and Klinman, N. R., *J. Immunol.* 1981. *127:* 194.

22 Gerhard, W., Yewdell, J., Frankel, M. E., Lopes, A. D. and Staudt, L., in Kennet, R. H., McKearn, T. J. and Bechtol, K. B. (Eds.), *Monoclonal Antibodies. Hybridomas: A New Dimension in Biological Analyses,* Plenum Press, New York 1980, p. 317.

23 Stuart-Harris, C. H., Schild, G. C. and Oxford, J. S., *Influenza. The Viruses and the Disease,* 2nd edition, Edward Arnold Publishers, London 1985.

24 Van Leeuwen, A., Goulmy, E. and Van Rood, J. J., *J. Exp. Med.* 1979. *150:* 1075.

25 Levy, R. G., Dower, S. K., Shearer, G. M. and Segal, D. M., *J. Exp. Med.* 1984. *159:* 1464.

26 Froscher, B. G. and Klinman, N. R., *J. Exp. Med.* 1986. *164:* 196.

27 Virelizier, J. L., Allison, A. C., Oxford, J. S. and Schild, G. C., *Nature* 1977. *266:* 52.

28 Dower, S. K., Ozato, K. and Segal, D. M., *J. Immunol.* 1984. *132:* 751.

29 Hackett, C. J., Askonas, B. A., Webster, R. G. and Van Wyke, K., *J. Exp. Med.* 1980. *151:* 1014.

30 Virelizier, J. L., Allison, A. C. and Schild, G. C., *Brit. Med. Bull.* 1979. *35:* 65.

31 Oldstone, M. B. A., Sissons, J. G. P. and Fujinami, R. S., in Fougereau, M. and Dausset, J. (Eds.), *Immunology 80 – Progress in Immunology IV,* Academic Press, New York 1980, p. 599.

32 Townsend, A. R. M., Gotch, F. M. and Davey, J., *Cell* 1985. *42:* 457.

33 Zinkernagel, R. M. and Rosenthal, K. L., *Immunol. Rev.* 1981. *58:* 131.

34 Townsend, A. R. M., Rothband, J., Gotch, F. M., Bahadur, G., Wraith, D. and McMichael, A. J., *Cell* 1986. *44:* 959.

RECOGNITION OF INSULIN ON MHC-CLASS-II-EXPRESSING L929 CELLS BY ANTIBODY AND T CELLS

B. Rubin ([1, 2]), **B. Malissen** ([2]), **P.N. Jørgensen** ([3]) and
J. Zeuthen ([3])

. ([1]) *Institute for Experimental Immunology,*
University of Copenhagen,
Nørre Allé 71, 3., DK-2100 Copenhagen
([2]) *CIML, Case 906, F-13288 Marseille Cedex 9 (France), and*
([3]) *Novo Biolabs, Novo Allé, DK-2880 Bagsværd (Denmark)*

SUMMARY

In the present experiments, we attempted to obtain evidence that T-cell receptors (Tcr) and immunoglobulins can react against the same antigen-peptide/MHC class II complexes on antigen-presenting cells (APC). Use was made of monoclonal APC, *i.e.* I-A^k α/β gene-transfected L929 fibroblasts, monoclonal anti-insulin antibodies and selected insulin-specific T-cell lines. Evidence for similarities in antibody and T-cell recognition of insulin presented by I-A^k α/β gene-transfected L-cell fibroblasts was not obtained after serious attempts. Furthermore, we found no evidence for synthesis of antibodies specific for insulin-peptide/MHC class II complexes.

KEY-WORDS: Insulin, MHC; APC, Peptide, Tcr.

INTRODUCTION

The central event in induction of immune responses is the activation of helper T cells by antigenic peptides associated with MHC class II molecules on APC [1, 2]. In contrast to this are antibody molecules that recognize soluble antigens or their fragments. However, since Tcr and antibody are of the same family and of rather similar overall structure [8], it is difficult to

understand why Tcr should react differently from antibody. One major difference in the two recognition systems is that Tcr molecules are cell-bound, whereas antibodies circulate in soluble form. Thus, the reactivity of Tcr may be guided by other T-cell membrane molecules such as CD4 molecules [7], rather than fundamentally differing from the reactivity of antibody molecules. In the present study, we attempted to search for similarities in antibody and T-cell recognition of insulin presented by I-A^k α/β gene-transfected L-cell fibroblasts.

MATERIALS AND METHODS

Animals.

Inbred mice were from the breeding facility of Statens Seruminstitut; they were C$_3$H/Sscl, B10.BR, B10.A and B10.A (4R), used at the age of 6-12 weeks and immunized with insulin in complete Freund's adjuvant (50 μg insulin/mouse). Thirty min before injection, the mice received 0.2 ml of 500 mg dextrose per ml to prevent hypoglycaemia.

Antigens and antibodies.

Crystallized insulin from pork or sheep (PIns or SIns) were obtained from Novo Biolabs. Eighteen mAb against BIns (bovine) or HIns (human) were obtained from Novo Biolabs [21]; mAb against MHC molecules were provided by Dr M. Pierres [13] or Dr A.F. Williams [11]. Horseradish peroxidase (HRP) coupled rabbit antimouse immunoglobulin antibodies were bought from Dakopatts (Copenhagen, Denmark).

Cells.

MHC-class-II gene-transfected L cells used in the present study were CA 14.11.14 (I-A^k) and CA 36.1.3 (I-E^k). They were cultured in HAT-containing 5 % FCS (foetal calf serum)/RPMI-1640 medium supplemented as before [10]. L929 (H-2^k) or IT.22 (H-2^q) fibroblasts were grown in medium without HAT. Ins-specific T-cell lines were produced as described previously [17] except that the responding CD4+/CD8$^-$ T cells were purified from lymph node/spleen cell mixtures [18].

ELISA.

The assay used has been described previously [15]. Insulins were coated to the microtitre plates at 10 μg/ml and the different fibroblasts were seeded at 10^5-2×10^5 cells/well. The only change in procedure was the use of either HRP-labelled second antibody or biotin-labelled mAb followed by HRP-labelled avidin.

APC	= antigen-presenting cell.		MHC	= major histocompatibility complex.
FCS	= foetal calf serum.		PIns	= pork insulin.
HIns	= human insulin.		SIns	= sheep insulin.
HRP	= horseradish peroxidase.		Tc	= T-cell receptor.
mAb	= monoclonal antibody.			

RESULTS

General protocol.

The following protocol was adapted for the experiments to be described: CA14 cells were incubated for 2 h with 500 µg Ins/ml of RPMI-1640 (R) at 37°C. Then, 10 % FCS/R was added to give a cell concentration of 10^6/ml and 100 µl were seeded in wells of microtitre plates. After overnight incubation at 37°C, the plates were washed with 1 % FCS/R, incubated for 1 h at 37°C and washed again. Then anti-insulin mAb were added and incubated for 3 h at 37°C followed by wash and incubation at room temperature with HRP-labelled rabbit anti-mouse Ig antibodies for 1 h. The enzyme reaction was performed at room temperature (15 min) and the OD^{492} was read in a spectrophotometer. Using TNP-PIns-coated ELISA plates and a purified anti-DNP mAb in the ELISA with HRP-labelled rabbit anti-mouse Ig antibodies, we could estimate that the following OD_{492} values corresponded to approximately the indicated number of Ab molecules per cell: 0.250 = 2,000/cell, 0.500 = 10,000/cell, 1,000 = 50,000/cell and 2,000 = 250,000/cell.

Detection of insulin on CA14 cells.

PIns and SIns were incubated with CA14 cells and insulin binding was detected by our anti-Ins mAb. A representative experiment is given in table I. The basic finding was that certain mAb reacted with one but not with the other insulin molecule when these were bound to the CA14 cells: OxI-004 reacted with SIns but not with PIns; HUI-018 reacted with PIns but not with SIns. OxI-002 reacted with both insulins and OxI-001, -003 and HUI-004 did not react with any of the insulins on CA14 cells (not shown).

TABLE I. — **Insulin-pulsed fibroblasts of different type react in a similar manner with anti-Ins mAb.**

| Target cells | Pulsed with | OD_{492} values in cellular ELISA Anti-Ins mAb: | | | |
		Medium	OxI-004	HUI-018	OxI-002	Anti-MHC
CA 14	SIns	0.057	*1.831*	-0.206	*1.322*	*1.919* [1]
	PIns	0.043	0.198	*1.708*	*1.023*	*1.823*
CA 36	SIns	0.083	*1.322*	0.173	*1.008*	*1.738* [2]
	PIns	0.079	0.168	*0.989*	*1.090*	*1.821*
L929	SIns	0.113	*0.867*	0.073	*1.390*	*2.000* [3]
	PIns	0.089	0.098	*1.029*	*1.239*	*2.000*
IT.22	SIns	0.097	*1.486*	0.211	*1.078*	*1.321* [4]
	PIns	0.045	0.270	*1.173*	*1.196*	*1.557*

Target cells were pulsed with SIns or PIns for 18 h at 37°C before ELISA. Anti-MHC antibodies: (1) Ox6 = anti-I-A^k, (2) 41.A = anti-I-E^k, (3) H100-R5/28 = anti-K^k, (4) H117 = B6 anti-CBA anti-serum.

Insulin binding to different cells.

We analysed whether the I-A^k molecules on CA14 cells were responsible for the differential expression of PIns *versus* SIns determinants. The data in table I show that L929, IT.22 and CA36 cells orient PIns and SIns in the same way as do CA14 cells. This result and the finding that anti-MHC class II mAb do not inhibit insulin binding to CA14 or CA36 cells indicate that MHC class II molecules are not involved in the observed phenomenon.

T-cell reactivity against insulin-CA14 cells.

A T-cell line with specificity against both PIns and SIns was stimulated with L cells or CA14 cells incubated with either PIns or SIns for 1-18 h at 37°C. Results in table II show that a 2-h incubation period of insulin and CA14 cells was enough for efficient insulin presentation, whereas the T-cell lines were not stimulated by L cells and insulin. Activation of T cells by insulin-CA14 cells was inhibited by anti-I-A^k mAb and by anti-CD4 mAb.

A search for mAb against insulin-Ia complexes.

As the anti-Ins mAb used here are directed against native conformational determinants, they may not recognize insulin fragment/Ia complexes.

TABLE II. — Antibody and T-cell interaction
with insulin-pulsed CA14 cells.

APC	Inc. time	P/SIns-1 T-cell proliferation in the presence of:			ELISA OD$_{492}$
		medium	Ox6	H129	OxI-002
PE/Spl-SIns	—	39.371	8.035	3.391	ND
PE/Spl-PIns	—	18.352	3.956	4.477	ND
CA 14-SIns	2 h	18.891	3.055	4.124	0.087
CA 14-PIns	2 h	10.083	2.889	2.573	0.109
CA 14-SIns	6 h	23.578	5.344	5.127	0.134
CA 14-PIns	6 h	15.731	3.807	4.015	0.209
CA 14-SIns	18 h	28.343	4.881	4.811	1.534
CA 14-PIns	18 h	17.558	3.557	4.553	1.497
L929-SIns	18 h	1.057	983	954	1.337
L929-PIns	18 h	571	874	761	1.503

PE/Spl: mixture of PE and spleen cells were mitomycin-C-treated (50 μg/ml) and insulins (50 μg/ml) were present during the 4-day culture period (last 24 h in the presence of ^{3}H-thymidine). CA 14 or L cells were pulsed at 37°C with insulin 1 hour less than indicated, and mitomycin-C (100 μg/ml) added for 1 h. Then they were washed and used as APC. Data are proliferative responses of 5×10^4 responding T cells from line P/SIns-1. An aliquot of the insulin-pulsed APC were controlled for reactivity with anti-Ins mAb = OxI-002.

TABLE III. — **No evidence for insulin-Ia complex-specific antibodies.**

| Mice | Inhibitor | OD$_{492}$ values from ELISA | | | |
		4 weeks	3 months	6 months	18 months
C$_3$H/Sscl	−	0.869	0.931	1.156	1.236
	+	0.079	0.119	0.257	0.155
B10.BR	−	0.534	0.832	1.657	1.334
	+	0.152	0.279	0.199	0.089
B10.A	−	0.788	0.781	0.993	1.003
	+	0.177	0.203	0.189	0.081
B10.A (4R)	−	0.489	0.934	1.338	0.972
	+	0.188	0.237	0.202	0.131

Groups of 20 mice were immunized with 50 μg SIns in CFA and boosted every month with SIns in IFA intraperitoneally and subcutaneously, alternatively. Bleedings were performed 7 days after injection. Antisera were titrated in cellular ELISA against SIns-CA14 cells (the present data) or SIns-CA36 cells (not shown). Values are from individual mice (representative of the group); antisera were diluted 1/20 (4 weeks), 1/100 (3 months) or 1/200 (6 or 16 months); NMS diluted 1/20-1/100 gave ELISA values of 0.050-0.120.

Inhibitor: 10^{-4} M SIns + antiserum dilutions were incubated for 24 h at 37°C before ELISA. The same results were obtained when anti-SIns antisera were incubated for only 30 min with 10^{-4} M SIns before ELISA.

Therefore, we screened antisera from about 300 mice hyperimmunized against SIns for more than a year. The antisera pretreated with insulin were analysed against SIns-pulsed CA14 or CA36 cells in the presence of free insulin, *i.e.* an assay system that would favour detection of antibodies specific for insulin-Ia complexes. In none of more than 1,500 bleedings did we find any sign of antibodies specific for insulin-Ia complexes (table III). In addition, we found that the different antisera did not inhibit T-cell proliferation induced by SIns-pulsed CA14 cells (not shown).

DISCUSSION

Our basic finding was that a panel of 18 anti-insulin mAb directed towards different common epitopes on insulin molecules reacted differently with PIns or SIns incubated with MHC class II gene-transfected fibroblasts (table I). Lack of reactivity of a given mAb (*e.g.* OxI-004 against PIns-CA14 cells but not against SIns-CA14 cells) could be due to (1) processing of insulin molecules with subsequent differential loss of that particular epitope; (2) processed insulin bound to a membrane molecule that blocks the particular epitope on PIns but not on SIns. The following membrane molecules were apparently not involved: MHC class II molecules (table I), Fc receptors (not shown), MHC class I molecules (table I and the fact that anti-MHC class I mAb had only moderate effects on insulin binding to fibroblasts) or insulin receptors (there are only about 1,000 insulin receptors/fibroblast). The fact that the

OxI-004 epitope of SIns but not of PIns (and vice versa for the HUI-018 epitope) is intact after 18-h incubation at 37°C with L929, IT.22, CA14 or CA36 cells may indicate either (1) that the enzymatic machinery in all four cell types cleaves SIns or PIns differently and this despite the fact that SIns and PIns differ only in three amino acids in the α-loop of the A-chain; or (2) that « peptide » binding membrane molecules [4, 9, 12] can present processed insulin differentially on the cell surface.

The smallest version of processed insulin recognized by T cells seems to be A1-A14/B7-B15 [14]. This molecule presented on the cell membrane may contain the OxI-004 epitope, as this mAb reacts with insulin-des-B23-30, oxidized α-chains [21] and lightly trinitrophenylated insulin (TNP coupled to amino acid B29) (not shown). The fine specificity of HUI-018 mAb is not known, except that most reactivity with insulin is lost after trinitrophenylation (not shown). The biological significance of the observed phenomenon is unknown: a 2-h incubation at 37°C of insulin with CA 14 cells was sufficient for formation of insulin-MHC class II complexes capable of activating T-cell proliferation, whereas approximately 18 h were needed for antibody recognition (table II). Thus, either T cells and mAb recognize different forms of processed insulin or T cells need less membrane-bound, processed insulin than can be detected by mAb in our assay ($=$ 2,000 molecules/cell). However, our results demonstrate that processed insulin can be recycled to the outer membrane in the absence of MHC class II molecules.

Continued immunization with antigens leads to formation of antisera, which are more and more cross-reactive with other antigens [3, 16]. We thought that this might be due to synthesis of antibodies against more and more degraded antigen: hyperimmunization leads to induction of B cells, which could produce anti-peptide antibodies or MHC-restricted antibodies [5, 6, 19, 20]. However, by analysis of more than 1,500 antiserum samples taken at different times after immunization with insulin, we did not find any antibodies which could be classified as anti-peptide or MHC-restricted antibodies; that is, which reacted with insulin-pulsed CA14 or CA36 cells in excess of free insulin. As insulin-pulsed CA14 cells activate T cells, anti-peptide or MHC-restricted antibodies, if they are produced at all, may be directed against insulin-Ia complexes present in less than 2,000 complexes per cell.

Thus, within the limits of present technology, we may have to conclude that functional antibody and T-cell recognition is very different.

REFERENCES

[1] BABBITT, B.P., ALLEN, P.M., MATSUEDA, G., HARBER, E. & WAINE, E.R., Binding of immunogenic peptides to Ia histocompatibility molecules. *Nature* (Lond.), 1985, **317**, 359-361.

[2] BUUS, S., SETTE, A., COLON, S.M., MILES, C. & GREY, H., The relationship between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. *Science,* 1987, **235**, 1353-1358.

[3] CHESNUT, R.N., ENDRES, R.O. & GREŸ, H., Antigen recognition by T cells and B cells: recognition of cross-reactivity between native and denatured forms of globular antigens. *Clin. Immunol. Immunopath.,* 1980, **15**, 397-408.

[4] DELOVITCH, T.L., PHILLIPS, M.L., NAQUET, P., YIP, C.C., LIN, J. & SKINNER, M., Studies on the mechanism of processing and presentation of insulin by antigen-presenting cells, *in* «Mediators of immune regulation and immune therapy» (Singhal, S.K. & Delovitch, T.L.) (pp. 15-30). Elsevier Sciences Publ., Amsterdam, 1986.

[5] FROSCHER, B.G. & KLINMAN, N.R., Immunization with SV-40 transformed cells yields mainly MHC-restricted monoclonal antibodies. *J. exp. Med.,* 1986, **164**, 196-210.

[6] IVANYI, P., LIMPENS, J. & LEUPERS, J., MHC-restricted antibodies. *J. cell. Biochem.,* 1984, (Suppl. 8A), 211-223.

[7] JANEWAY, C.A., HAQUE, S., SMITH, L.A. & SAIZAWA, K., The role of the murine L3T4 on activation by monoclonal anti-receptor antibodies. *J. mol. Cell. Immunol.,* 1987, **3**, 121-131.

[8] KRONENBERG, M., SIU, G., HOOD, L. & SHASTRI, N., The molecular genetics of the T-cell antigen receptor and T-cell antigen recognition. *Ann. Rev. Immunol.,* 1986, **4**, 529-591.

[9] LAKEY, E.K., MARGOLIASH, E. & PIERCE, S.K., Identification of a peptide-binding protein that plays a role in antigen presentation. *Proc. nat. Acad. Sci.* (Wash.), 1987, **84**, 1659-1663.

[10] MALISSEN, B., SHASTRI, N., PIERRES, M. & HOOD, L., Cotransfer of the $E\alpha^d$ and $A\alpha^d$ genes into L cells results in the surface expression of a functional mixed-isotype Ia molecule. *Proc. nat. Acad. Sci.* (Wash.), 1986, **83**, 3958-3963.

[11] McMASTER, W.R. & WILLIAMS, A.F., Monoclonal antibodies to Ia antigens from rat thymus: cross-reactions with mouse and human and use in purification of rat Ia glycoproteins. *Immunol. Rev.,* 1979, **47**, 117-137.

[12] NAIRN, R., SPENZLER, M.L., HOFFMANN, M., SOLVAY, M.J. & THOMAS, D.W., Macrophage processing of peptide antigens: identification of an antigenic complex. *J. Immunol.,* 1984, **133**, 3225-3230.

[13] NAQUET, P., MARCHETTO, S. & PIERRES, M., Dissection of the CAT-specific T-cell repertoire in H-21^k mice. — II. The use of monoclonal antibodies to study the recognition of Ia antigens by CAT-reactive T-cell clones. *Immunogenet.,* 1983, **18**, 559-574.

[14] NAQUET, P., ELLIS, J., SINGH, B., HODGES, R.S. & DELOVITCH, T.L., Processing and presentation of insulin. *J. Immunol.,* 1987, **139**, 3955-3963.

[15] RENINGER, L., FUERI, J., BONED, A., PRAT, M., LANDOLFO, S. & RUBIN, B., On the molecular basis of T-helper cell function. — IV. B-lymphocyte-promotor factors: on their mode of action, biochemical nature and possible relationship to molecules involved in specific T-helper cell activity. *Cell. Immunol.,* 1985, **92**, 85-104.

[16] RUBIN, B., «Antibody formation against human serum albumin in rabbits». Master's Degree thesis. Univ. Copenhagen 1968, pp. 1-87.

[17] RUBIN, B. & BONED, A., Insulin-specific T-cell help to TNP-specific B cells requires activation via the antigen T-cell receptor. *Europ. J. Immunol.,* 1986, **16**, 1223-1229.

[18] RUBIN, B., GEISLER, C., KUHLMANN, J. & PLESNER, T., Isolation of helper T cells from non-responder mice. 1989 (in press).

[19] TITUS, R.G. & CORRADIN, G., Inhibition and enhancement of *in vitro* helper activity of apocytochrome c-specific murine T-cell populations and clones by antiapocytochrome c-specific monoclonal antibodies. *Europ. J. Immunol.,* 1986, **16**, 729-733.

[20] VAN LEEUWEN, A., GOULMY, E. & VAN ROOD, J.J., Major histocompatibility complex-restricted antibody reactivity mainly, but not exclusively, directed against cells from male donors. *J. exp. Med.,* 1979, **150**, 1075-1093.

[21] WU, C.Y., JØRGENSEN, P.N., PATKAR, S.A., KRUSE, V., HEDING, L.G. & ZEUTHEN, J., Characterization of monoclonal antibodies against bovine insulin. *Ann. Inst. Pasteur/Immunol.,* 1986, **137 C**, 11-23.

Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1–MAGE-A1 from a nonimmunized phage-Fab library

Patrick Chames*, Simon E. Hufton†, Pierre G. Coulie‡, Barbara Uchanska-Ziegler§, Hennie R. Hoogenboom†¶‖

Department of Pathology, ¶Maastricht University, and *University Hospital Maastricht, P.O. Box 5800, 6202AZ Maastricht, The Netherlands; †Target Quest B.V., Provisorium, P.O. Box 5800, 6202AZ Maastricht, The Netherlands; ‡Catholic University of Louvain, Cellular Genetics Unit, B-1200 Brussels, Belgium; and §Institut für Immungenetik, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Spandauer Damm 130, Berlin, D-14050, Germany

Antitumor antibodies with the same specificity as cytotoxic T lymphocytes that recognize antigenic peptides encoded by tumor-associated genes and presented by MHC class I molecules would be valuable tools to analyze the antigenicity or target tumor cells *in vivo*. To obtain a human antibody directed against a peptide encoded by gene melanoma-associated antigen (MAGE)-A1 and presented by HLA-A1 molecules, we selected a large phage Fab antibody repertoire on a recombinant version of the complex HLA-A1–MAGE-A1 produced by *in vitro* refolding. One of the selected phage antibodies shows binding to HLA-A1 complexed with the MAGE-A1 peptide, but does not show binding to HLA-A1 complexed with a peptide encoded by gene MAGE-A3 and differing from the MAGE-A1 peptide by only three residues. Phages carrying this recombinant antibody bind to HLA-A1$^+$ cells only after *in vitro* loading with MAGE-A1 peptide. These results indicate that nonimmunized phage Fab libraries are a source of antibodies with a T cell antigen receptor-like specificity. The human anti-HLA-A1–MAGE-A1 antibody described here may prove very useful for monitoring the cell surface expression of these complexes, and eventually, as a targeting reagent for the specific immunotherapy of HLA-A1 patients bearing a MAGE-A1-positive tumor.

phage display | major histocompatibility complex | T cell antigen receptor-like antibodies | tumor targeting

The past few years have seen the resurgence of a strong interest in tumor vaccine development (1). This is in part attributable to an increased understanding of the immune response to tumors, especially in the case of melanomas. It is now well established that human melanoma cells often express antigens that are recognized by cytotoxic T lymphocytes (CTL) derived from tumor-bearing patients. These CTLs have been used as tools to identify genes that code for tumor antigens, such as those of the melanoma-associated antigen (MAGE) gene family, which includes at least 17 related genes, namely MAGE-A1 to A12, MAGE-B1 to B4, and MAGE-C1 (2). The MAGE genes are expressed by tumors of various histological types, but they are silent in normal cells, with the exception of male germ-line cells that do not carry HLA class I molecules and are therefore unable to present antigens to CTL. Hence, antigens encoded by MAGE-A, -B, or -C genes should be strictly tumor specific. Because the MAGE antigens are shared by many tumors and on account of their strict tumor specificity, they are of particular interest for cancer immunotherapy.

Gene MAGE-A1 was isolated because it encoded an antigen presented on HLA-A1 molecules to autologous CTL of a melanoma patient (3). It is frequently expressed in metastatic melanomas (48%), esophageal squamous cell carcinomas (53%), head and neck squamous cell carcinomas (28%), non-small cell lung carcinomas (49%), or the bladder carcinomas (22%). The antigenic peptide presented by HLA-A1 molecules is EADPT-

GHSY (4). Several other MAGE-A1 epitopes recognized by CTL have been identified. These are presented by HLA-A3, -A24, -A28, -B53, -Cw2, -Cw3, and -Cw16 (5).

Although there is ample evidence for the presence of these antigens on a variety of tumors, they are seemingly unable to elicit an adequate antitumor immune response. Many modern cancer immunotherapies are therefore designed to induce or enhance T cell reactivity against tumor antigens. Clinical trials involving therapeutic vaccination of cancer patients with antigenic peptides or proteins are in progress (4). In a recently completed trial, 25 tumor-bearing HLA-A1 melanoma patients with advanced disease received three s.c. injections of a MAGE-A3 peptide presented by HLA-A1 (6). Tumor regression was observed in seven patients; three of these were complete. No increase in anti-MAGE CTL could be detected in the blood of these patients, including those with tumor regression. These regressions occurred very slowly, suggesting that they may have been caused by a weak immune response. To explain how these tumor regressions are obtained, and why the majority of patients do not appear to respond to the vaccines, one wishes to have precise information about the presence of the target tumor antigen on the tumor cell surface, before and after the vaccination. Currently, expression of MAGE-A and HLA class I genes is assessed with reverse transcription–PCR on tumor samples, or by immunological detection of certain MAGE-A proteins in tumor cells (7), by using a mAb such as 57B that detects MAGE-A4 in tissues, and with mAb W6/32HL that detects the presence of mature HLA class I molecules. However, positive results from these assays do not imply display of the antigenic complex. Multiple protein interactions are required for efficient assembly of MHC class 1 heavy chain and β2 microglobulin (β2m) with endogenous peptides (8). Peptide processing and transport into the endoplasmic reticulum involves the transporters associated with antigen processing, (TAP-1 and TAP-2), and the proteasome complex, which also includes the MHC-encoded low molecular weight proteins LMP-2 and LMP-7 (8). Loss of expression or down-regulation of any of these proteins may allow tumor cells to escape recognition by CD8$^+$ CTLs (9). Similarly, it has been shown that a mutation in the β2m gene is a frequent event leading to the loss of HLA class I surface expression in melanomas (10). Thus, a direct visualization of the HLA-A1–MAGE-A1 complex on the tumor cell surface would be the ideal way to ensure its presence. Soluble T cell receptors

IMMUNOLOGY

would be ideal for this purpose. Unfortunately, it has been proven difficult to engineer these molecules (11) and their inherent low affinity for their target may limit their use as detection reagents. Antibodies that specifically recognize a peptide–MHC complex have already been used to study MHC class I or II antigen presentation (12–18), to localize and quantify antigen-presenting cells (APC) displaying a T cell epitope (13, 19–21), specifically mask an autoimmune T cell epitope (22, 23), or as a targeting tool in a mouse model (24). However, selecting such reagents remains a difficult task and several failures have been reported (25, 26). The available antibodies have been obtained after immunization of mice with recombinant peptide–MHC complexes or peptide-loaded TAP-deficient APC, and recently by selection from phage-antibody libraries made from immunized transgenic mice (27). Immunization with such complexes is extremely time-consuming. Moreover, all these antibodies are of murine origin, and cannot be used repetitively in patients because of the likely development of a human anti-mouse antibody response.

We report here the selection of a fully human Fab fragment directed against the HLA-A1–MAGE-A1 complex by selection from a large nonimmune phage-antibody repertoire.

Materials and Methods

Cloning of HLA-A1 Heavy Chain. The cDNA of the HLA-A*0101 allele was amplified by PCR with the primers 5'-GCGGCG-GCGGCC*A*T*GG*GCTCCCACTCCATGAGG-3' and 5'-CG-GCAGGAGAG*CGGCCGC*GAGCTCCCATCTCAGGG-3' (Eurogentec, Seraing), containing the underlined *Nco*I and *Not*I restriction sites, respectively. The PCR products were ethanol precipitated, digested with *Nco*I and *Not*I enzymes, gel purified, and ligated into the plasmid pET21d (Novagen) digested with the same enzymes. The constructs were transformed into *Escherichia coli* strain DH5α and some clones containing an insert were sequenced. Clones with a correct sequence were then transformed into *E. coli* strain BL21DE3 for production. The plasmid pHNβ2m was used to produce the β2m (28), also in *E. coli*.

In Vitro Refolding of the Peptide–MHC Complexes. The peptide–MHC complexes were *in vitro* refolded from inclusion bodies produced in *E. coli* as described (28).

Biotinylation of the Refolded Complex. Centricon-10 units were used to exchange the buffer for 50 mM $NaHCO_3$ and concentrate the complex to 1 mg/ml. EZ-link sulfo NHS-SS biotin (0.01 volume of 10 mM; Pierce) was added (a final concentration of 100 µM corresponds to a 5:1 ratio of biotin:complex) and the solution was incubated for 30 min at room temperature. The biotinylated complex was separated from the free biotin by gel filtration on a Superdex 200 column (Amersham Pharmacia).

Monoclonal Antibodies. The mAb W6/32HL (anti-HLA class I heavy chain/β2m complexes), W6/32HK (inactive variant of W6/32.HL), HB28 (BBM1) (anti-human β2m), HC-A2 (anti-HLA-A heavy chains), and TÜ155 (anti-HLA-A/β2m complexes with peptide-dependent reactivity) have been described (29–31). TÜ114 (IgMₖ) was produced by standard techniques and recognizes HLA-A–β2m complexes independent of the presence of peptide in the binding groove.

Selection of Phage-Antibodies on Biotinylated Complexes. A large human Fab library containing 3.7×10^{10} antibody fragments was used for the selection (32). Phages (10^{13}) were first preincubated 1 h at room temperature in 2% nonfat dry milk-PBS in an immunotube coated with streptavidin (10 µg/ml) to deplete for streptavidin binders. Streptavidin–coated paramagnetic beads (200 µl; Dynal, Oslo) were also incubated in 2% milk-PBS for 1 h

at room temperature. Phages were subsequently incubated for 1 h with decreasing amounts of biotinylated complexes (500, 100, 20, and 4 nM for rounds 1–4, respectively). Streptavidin beads were added, and the mixture was left for 15 min on a rotating wheel. After 15 washes with 0.1% Tween-PBS, bound phages were eluted by a 10-min incubation with 60 µl of 50 mM DTT, thus breaking the disulfide bond in between the complex and the biotin. The eluted phages were diluted in PBS to 1 ml and 0.5 ml were used to infect *E. coli* strain TG1 cells grown to the logarithmic phase (OD_{600} of 0.5). The infected cells were plated for amplification as described (33). After infection of TG1 cells for 30 min at 37°C, bacteria were grown overnight at 30°C on agar plates.

The diversity of the selected antibodies was determined by means of DNA fingerprinting (34). The insert of different clones was amplified by PCR with primers pUC-reverse (5'-AGCGGATAACAATTTCACACAGG-3') and fd-tet-seq24 (5'-TTTGTCGTCTTTCCAGACGTTAGT-3') and digested with the enzyme *Bst*NI before analysis on agarose gel.

Phage ELISA. Specificity of individual Fab fragments was assessed by ELISA with indirectly coated complexes as described (35).

Flow Cytometry Analysis on Peptide-Loaded Cells. The Epstein–Barr virus (EBV)-transformed B cell lines MZ2 (A1, A29, B37, B44, Cw6, and Cw16), LG2 (A24, A32, B35, B44, and Cw6), and AVL3 (A1, A2, B27, B44, Cw5, and Cw7) or melanoma cell lines MZ2-MEL 3.0 and MZ2-MEL 2.2 (3), were stained to demonstrate the ability of fd-Fab-G8 to bind the native HLA-A1–MAGE-A1 complex. About 10^6 cells were used for each experiment. B cells were washed twice in PBS, incubated for 30 min at 37°C in PBS containing 100 µM peptide, and then washed twice again with ice-cold 2% milk-PBS. Melanoma cells were directly resuspended in 2% milk-PBS. All subsequent washes and incubations were done in ice-cold 2% milk-PBS. Cells were incubated for 1 h at 4°C with phage-antibodies (1×10^{10} cfu) in 100 µl, washed three times, incubated with 100 µl of goat anti-fd polyclonal antibody (diluted 1/500), washed three times again and finally incubated with 100 µl of FITC-conjugated rabbit anti-goat antibody (Dako; diluted 1/50). After three washes, cells were resuspended in 500 µl of ice-cold PBS. Detection of fluorescent cells was performed by means of flow cytometry on a FACScalibur (Becton Dickinson) and the results were analyzed with the CELLQUEST program (Becton Dickinson).

Measurements of Fab–Antigens Interaction by BIAcore Biosensor. Fab-G8 was purified from *E. coli* periplasmic fraction as already described (32). Kinetic measurements were performed by surface plasmon resonance. PBS (pH 8)/0.05% Tween20 was chosen as running buffer. An NTA-chip (Amersham Pharmacia) was activated with 500 µM $NiCl_2$ for 1 min at 10 µl/min. Approximately 800 response units of hexahistidine-tagged Fab (20 µg/ml) was immobilized and the peptide–MHC complexes were subsequently injected at a flow rate of 20 µl/min to minimize rebinding effects. A blank (injection of the antibody only) was subtracted to each curve to take in account the slightly decreasing baseline caused by the Fab dissociation. The channel was regenerated by injection of 250 mM EDTA during 2 min (36).

Results

Production of HLA-A1-β2m–Peptide Complex. HLA-A1 heavy chains and β2m were produced as inclusion bodies in an *E. coli* expression system. The yields of purified inclusion bodies were 25 and 36 mg/l for the heavy chain and β2m, respectively. Recombinant products of the expected sizes (33 and 12 kDa for HLA-A1 and β2m, respectively) were visualized with SDS/PAGE analysis (Fig. 1*A*). An additional band, presumably

Fig. 1. (A) Analysis of purified inclusion bodies by SDS/PAGE and Coomassie staining. Two microliters of HLA-A1 (lane 1) or β2m (lane 2) inclusion bodies in freezing buffer were loaded on the gel. The expected size of the full-length heavy chain product is indicated with an arrow. (B) Gel filtration profile of the folding mixture, after an incubation of 36 h at 4°C. The mixture was concentrated by ultracentrifugation and loaded on a Superdex 200 column. The shoulder after peak 3 is a component of the folding buffer. (C) SDS/PAGE analysis and Coomassie staining of the peaks obtained by gel filtration. Lanes 1-3 correspond to 20 μl of fractions from peaks 1-3, respectively.

corresponding to a degradation product, was detected in the heavy chain preparation. However, this did not seem to interfere with further experiments. The purified inclusion bodies were dissolved in urea buffer. The heavy chain and β2m solutions were then diluted in a folding buffer, in the presence of the MAGE-A1 peptide, and the complexes were allowed to fold over 36 h at 4°C. The mixture was submitted to gel filtration and three major peaks were observed (Fig. 1B). SDS/PAGE analysis indicated that the first peak, with a molecular weight of ≈48 kDa, contained HLA-A1 heavy chain and β2m (Fig. 1C). This peak was absent from a control folding experiment conducted in the absence of antigenic peptide. We concluded that it corresponded to HLA-A1–β2 m–MAGE-A1 peptide complexes. The second peak corresponded to β-lactamase and the third peak was composed of free β2m. Under these conditions, up to 1.2 mg of purified complexes could be obtained from a refolding experiment by using 6 mg of heavy chain, 5 mg of β2m, and 2 mg of peptide. Thus, the observed yield was ≈10%.

Assessment of Correct Folding of the Recombinant Complexes. We verified that the recombinant complex could stimulate CTL clone 82/30, which specifically recognizes the MAGE-A1 peptide (EADPTGHSY) presented by HLA-A1 molecules (37). The CTL clone produced tumor necrosis factor when incubated in microwells coated with the HLA-A1–MAGE-A1 complex (Fig. 2A). No production of tumor necrosis factor was observed when CTL 82/30 was incubated with a recombinant HLA-A2–MAGE-A3 complex produced and purified with the same methods as for the HLA-A1–MAGE-A1 complexes. The HLA-A1–MAGE-A1 complexes did not stimulate another CTL clone that recognizes a peptide presented by HLA-A2 molecules. We concluded that at least a fraction of the HLA-A1–MAGE-A1 complexes were folded in such a way that they could bind the T cell receptors displayed by the specific CTL clone.

We decided to biotinylate the complexes to avoid a possible conformational change of the molecules caused by passive absorption onto plastic during phage library selection procedures. The coupling reagent was chosen to possess a disulfide bond between the reactive group and the biotin. This allowed for easy separation of the complex with bound phage-antibody from biotin-streptavidin particles by using reducing conditions. Biotinylated complexes were added to streptavidin-coated wells and their recognition by a panel of anti-HLA mAb was compared with aggregates and β2m (Fig. 2B). They were recognized by


Fig. 2. (A) T cell activation assay with the recombinant HLA-A1–MAGE-A1 complexes. Microwells were coated with the indicated concentrations of HLA-A1–MAGE-A1 (A1MA1) or HLA-A2–MAGE-A3 (A2MA3) complexes, and washed. CTL clones 82/30 (anti-HLA-A1–MAGE-A1) or 413/13 (against a peptide presented on HLA-A2 molecules) were added at 3,000 cells per well. After 24 h, the concentration of TNF present in the culture medium was measured by testing its cytotoxicity on the TNF-sensitive WEHI-164c13 cells. (B) ELISA with anti-HLA mAbs. Equivalent amounts of proteins were coated directly on plastic (striped, aggregates; gray, β2m; and white, complex) or on streptavidin-coated plastic (black, biotinylated complex) and binding of several mAbs was tested. PBS, no antibody; W6/32, mAb W6/32HL binding to heavy chain–β2m dimers; HK, inactive mutant of W6/32HK; HB28, mAb binding to β2m; HC-A2, mAb binding to a nonconformational epitope of HLA molecules; and TÜ114 and TÜ155, two conformation-sensitive mAbs.

antibody W6/32HL which recognizes heavy chain-β2m dimers (29), the anti-β2m antibody HB28, antibody HC-A2 which recognizes a nonconformational epitope on HLA class I molecules (30), and two conformation-sensitive antibodies recognizing HLA-A–β2m complexes either in the presence (TÜ155) or also absence (TÜ114) of a peptide in the groove (31). Conversely, the aggregates were only recognized by HC-A2 and HB28. These results confirmed the correct conformation of the biotinylated complexes.

Selection of Recombinant Anti-HLA-A1–MAGE-A1 Antibodies from a Phage Display Library. In preliminary experiments, phage displaying a large repertoire (3.7 × 10^10 of human recombinant Fab fragments) (32) were incubated with the biotinylated complexes and subsequently incubated with streptavidin-coated beads. To avoid the selection of antistreptavidin antibodies, the phage population was preincubated on streptavidin-coated immunotubes before selection and the bound phages were eluted with DTT. Breaking the disulfide bond between the biotin and the HLA-A1–MAGE-A1 complexes prevented the retrieval of phage bound to streptavidin. A 117-fold enrichment was obtained after four rounds of this selection procedure, and 92 clones out of 94 were binding to the HLA-A1–MAGE-A1 complexes. Without these precautions, only streptavidin-binding phage antibodies were isolated (data not shown).

The diversity of the selected antibodies was assessed by means of DNA fingerprinting, identifying 14 different patterns. The fine specificity of clones representative of each pattern was analyzed by ELISA on wells coated with HLA-A1 complexes containing either the MAGE-A1 (EADPTGHSY) or the MAGE-A3 (EVDPIGHLY) peptides, which differ by only three residues (Fig. 3). For most antibodies (11/14), no difference was

Fig. 3. Examples of specificity of recombinant antibodies selected for binding to HLA-A1–MAGE-A1 complexes. Microwells were coated with biotinylated BSA, washed, incubated with streptavidin, washed, and incubated with biotinylated HLA-A1–MAGE-A1 (black bars) or HLA-A1–MAGE-A3 (white bars) complexes. Suspensions of phages displaying the recombinant Fab fragments were then added. After washing, bound phages were detected with a mAb recognizing the p8 protein. Positive and negative controls were mAbs TÜ155 and W6/32HK (HK), respectively.

Fig. 5. Labeling EBV-transformed B cells with phage-antibody fd-Fab-G8. Cells were incubated with 100 μM peptide MAGE-1-A1 (thick lines) or MAGE-3-A1 (thin lines), and labeled with fd-Fab-G8 or a control fd phage. Bound phages were detected by sequential incubations with polyclonal goat anti-fd antibodies and rabbit anti-goat Ig antibodies coupled to fluorescein.

observed for the binding assay to either of the two peptides. Two antibodies, such as clone D2, appeared to bind slightly better to the complexes containing the MAGE-A1 peptide. One recombinant antibody, G8, bound to HLA-A1–MAGE-A1 but not at all to HLA-A1–MAGE-A3 complexes.

Characterization of Recombinant Fab Fragment G8. The soluble Fab fragment G8 was purified by metal affinity chromatography from the periplasm of *E. coli* by using the hexahistidine tag fused to its CH1 domain (32). Approximately 1 mg of pure material could be obtained from 1 liter of culture medium. The specificity of Fab-G8 was analyzed by surface plasmon resonance in a BIAcore instrument. In a classical-binding experiment, with the antigen immobilized on the chip, we could not find conditions that eluted the antibody without also dissociating the β2m from the HLA-A1 heavy chain. We resorted to immobilizing antibody Fab-G8 through its hexahistidine tag, and running the complexes in the soluble phase. These experiments confirmed that Fab-G8 bound to HLA-A1–MAGE-A1 but not to HLA-A1–MAGE-A3 complexes (Fig. 4). Binding to HLA-A1–MAGE-A1 occurred with on- and off-rates of 1.8×10^5 $M^{-1} \cdot s^{-1}$ and 0.045 s^{-1}, respectively, resulting in a K_D (k_{off}/k_{on}) of 250 nM.

Binding of fd-Fab-G8 to Cells Carrying the HLA-A1–MAGE-1 Antigen. Preliminary experiments indicated that a binding of the purified Fab-G8 could not be visualized on HLA-A1 cells incubated with the MAGE-A1 peptide. This was not surprising, considering the low affinity of the recombinant antibody and the low antigen density on the cell surface. To increase the avidity of the interaction, we recloned the Fab-G8 gene for display on fd

phage. This expression system does not need a helper phage and the resulting avidity is therefore higher than with the phagemid system in which the antibody–gp3 fusion product competes with wild-type gp3 during assembly of the capsid.

EBV-transformed B cells that did or did not express the HLA-A1 gene were incubated first with the MAGE-A1 or MAGE-A3 peptides. These cell lines are TAP$^+$. Consequently, only a minor fraction of HLA molecules can be loaded by this method, whereas the vast majority still displays endogenous peptides. The cells were washed, and incubated further with a suspension of fd-Fab-G8 phage. Bound phages were detected by sequential incubations with polyclonal goat anti-fd antibodies and rabbit anti-goat Ig antibodies coupled to fluorescein (Fig. 5). For the two HLA-A1 EBV-B cell lines that were tested, a shift in fluorescence intensity was observed when the cells were incubated with the MAGE-A1 but not with the MAGE-A3 peptide or when the cells were used without loading (data not shown). No shift was observed with a fd phage displaying an anti-ras Fab antibody. Furthermore, no shift in fluorescence intensity was observed when fd-Fab-G8 was incubated with an HLA-A1$^-$ EBV-B cell line, loaded with MAGE-A1 or MAGE-A3. These results demonstrate that Fab-G8 specifically recognizes HLA-A1–MAGE-A1 antigenic complexes *in situ*.

Binding of fd-Fab-G8 to (Unloaded) Melanoma Cell Lines. To confirm that Fab-G8 was capable of binding endogenously generated peptide–MHC complexes that might be present at a much lower density on the cell surface, we repeated the flow cytometry experiments with HLA-A1$^+$ and MAGE-A1$^-$ or MAGE-A1$^+$

Fig. 4. BIAcore analysis of Fab fragment G8. Purified Fab-G8 was immobilized on an NTA-chip after NiCl$_2$ activation and the HLA-A1–peptide complexes were run in solution. Full lines: HLA-A1–MAGE-A1 complexes (top to bottom: 625, 542, 458, 375, 292, and 208 nM). Broken line: HLA-A1–MAGE-A3 complexes (625 nM).


Fig. 6. Labeling melanoma cell lines with phage-antibody fd-Fab-G8. Melanoma cells MZ2-MEL 3.0 (HLA-A1$^+$, MAGE-A1$^+$) or MZ2-MEL 2.2 (HLA-A1$^+$, MAGE-A1$^-$) were incubated with phage antibodies fd-Fab-G8 (thick lines) or control phage antibodies (thin lines). Bound phages were detected by sequential incubations with polyclonal goat anti-fd antibodies and rabbit anti-goat Ig antibodies coupled to fluorescein.

melanoma cell lines. fd-Fab-G8 gave the same fluorescence intensity compared with the control on HLA-A1$^+$, MAGE-A1$^-$ cells but a higher intensity was obtained for fd-Fab-G8 compared with the control when a MAGE-A1$^+$ cell line was used (Fig. 6). The fluorescence shift was moderate compared with *in vitro*-loaded B cells, but this has to be expected because melanoma cells are expressing a lower density of HLA molecules and natural antigen processing is thought to produce a low density of HLA-A1–MAGE-A1 complexes on the cell surface. These results show that fd-Fab-G8 is capable of binding to cells which express the MHC–peptide complex at a density most likely to be found on MAGE-A1-expressing tumor cells.

Discussion

In this work, we have chosen to employ a large nonimmunized repertoire of human Fab fragments (32) to directly select human reagents with fine specificity for HLA class I–MAGE-A1, a well-characterized tumor antigen already used in clinical trials (38, 39). Until now, the few approaches that have been successful in isolating such T cell antigen receptor-like antibodies have used sophisticated immunization protocols, involving the injection of recombinant complexes or TAP-deficient *in vitro* loaded APC in syngeneic or even MHC-transgenic mice (40). The obvious advantage of this technique is a strong enrichment for peptide–MHC binders, and the use of transgenic mice may be helpful in reducing the frequency of pan-MHC reactive antibodies. However, these approaches are very time-consuming and the murine origin of the selected antibodies is a major drawback to possible future therapeutic applications. Indeed, antibodies specific for this tumor-associated antigen may eventually be used as a targeting reagent to deliver toxins or cytokines (24) specifically to the tumor site. In search of a more generic method to isolate human antibodies to MHC–peptide complexes, we have explored the use of very large nonimmunized phage–antibody libraries.

We used the phage display technique to select human antibody fragments from a large nonimmune library. One of the crucial factors determining the success of this approach relates to the state of the antigen used for selection. The conformation of the antigen has to be as "natural" as possible. We tested several methods to produce a recombinant version of the complex needed for the selection, including secretion of a single-chain peptide–HLA molecule in *E. coli* periplasm and expression in *Drosophila* cells (data not shown), but only *in vitro* refolding from inclusion bodies produced in *E. coli* yielded enough correctly folded protein. Numerous HLA complexes (class I and II) have been refolded *in vitro*, including HLA-A2, -B27, -B35, -B53 -G, -E, DR2, and DRB, demonstrating the versatility of this method for HLA molecules (41–45). However, this is the first report describing the production of a recombinant HLA-A1. This recombinant complex was biotinylated to minimize conformational changes of the antigen that may occur as a consequence of passive adsorption onto plastic (46, 47).

Using direct selection *in solution* with this antigen, we could isolate 14 different antibodies binding to the complex, with one clone (G8) showing the capability to bind in a peptide-specific manner. This antibody fragment binds in ELISA to HLA-A1–MAGE-A1 but not to HLA-A1–MAGE-A3. These two peptides display only three aa differences. This extreme specificity could be confirmed by BIAcore experiments. More importantly, phages displaying G8 did not bind HLA-A1$^+$ cells unless they were *in vitro* loaded with MAGE-A1 peptide, demonstrating the absence of binding for HLA-A1 complexes loaded with endogenous peptides. MAGE-A1 and MAGE-A3 share the same main anchor residues for HLA-A1 (Asp in position 3 or P3, and Tyr in P9) and secondary anchor residue Pro in P4. Moreover, P1, P6, and P7 are also identical. The residue in P2 (Ala in MAGE-A1; Val in MAGE-A3) is

probably not important for binding because the side chain is thought to be buried in the groove (48). Interestingly, the remaining residues in P5 and P8 have their side chain pointing out of the groove in a molecular model of HLA-A1–MAGE-A3 (48). MAGE-A1 has in P5 and P8 two residues (Thr and Ser) displaying hydroxyl groups that can be involved in hydrogen bonds, conversely to the residues displayed by MAGE-A3 (Ile and Leu). Therefore, the residues in P5 and P8 have a high probability of being involved in the differential binding to CTL82/30 TCR as well as the Fab antibody G8.

As shown by surface plasmon resonance studies, Fab-G8 has an affinity of 250 nM for the complex HLA-A1–MAGE-A1. This rather low affinity was not expected because the Fab fragment was selected from a very large repertoire of 3.7 × 10^{10} independent clones. A large number of binders directed to diverse antigens have already been selected from this repertoire, most of them having an affinity in the 5–30 nM range (32). The fact that the Fab-G8 antibody survived four rounds of selection in competition with all of the pan-reactive antibodies is surprising, but might be explained by a high expression level, inducing a high display level of the Fab-p3 fusion protein on phage. No other peptide-specific binders could be selected from the library, and a depletion step with HLA-A1–MAGE-A3 complexes did not favor the selection of MAGE-A1-specific binders. Hence, such peptide-specific binders seem to be rare in the library despite its size. It has to be kept in mind that the targeted epitope is a peptide deeply buried inside the MHC molecule. Only between 100–300 Å of peptide bound to a MHC class I molecule is actually available for direct recognition (49). Antibodies binding to proteins contact usually 800 Å of their ligand (50). Consequently, peptide specificity can be obtained only if the major interactions between the antibody and the complex are made with the peptide. The present affinity may be sufficient for staining purposes, but is most likely too weak for *in vivo* targeting purposes. The next step is thus to mature the affinity of this antibody without losing its fine specificity. This goal is difficult to reach, because the HLA-A1 chain is thought to contribute to 65–85% of the (peptide–MHC)–antibody interface. To overcome this problem, we are now performing an affinity maturation of G8 by directed randomization of complementarity determining region H3, and reselection (51). Although it is not known which residues of the antibody are involved in the peptide recognition, it is predominantly the H3 loop that dominates in the antigen interaction. Indeed, a gain of up to 18-fold in affinity without loss of peptide specificity has already been achieved (Chames *et al.*, unpublished work). Moreover, these studies may also define which residues are directly interacting with the peptide and allow for more targeted affinity maturation. Furthermore, with such antigen–antibody interaction profiles, it may be possible to build antibody libraries with a propensity to bind HLA–peptide complexes in a peptide-specific manner.

We succeeded in selecting a human antibody binding specifically to the complex HLA-A1–MAGE-A1. This antibody may now be used to detect the presence of this specific T cell epitope by flow cytometry and possibly immunohistochemistry or immunoprecipitation and should be very useful for analysis of MAGE-1-based immunotherapies. Indeed G8, as Fab or phage-Fab, may be used to check the expression of this T cell epitope on tumor cells, before and during vaccination with MAGE-A1 peptide, or APCs loaded with MAGE-A1 (39). The display efficiency of this complex at the APC surface could also be monitored after transfection with MAGE-1 gene or after *in vitro* peptide loading.

G8 is the first human antibody directed against a class I peptide–MHC complex. This presents many opportunities. This human antibody is directed against a well-characterized

and very specific human tumor marker and in principle should be an interesting candidate as targeting moiety in an immunocytokine (52), immunotoxin (24), or in a bispecific antibody (53), in particular after antibody affinity maturation. However, the main limitation for all of these applications may be the density of the specific epitope on the cell surface. Indeed, only a small fraction of the 10^4-10^5 HLA-A1 complexes displayed per cell are expected to contain the MAGE-A1 peptide. Possibly a more sensitive and selective antitumor reactivity *in vivo* could be obtained by retargeting of T cell achieved by fusion of Fab-G8 with the CD3 ζ or γ chain (54, 55). Preliminary data suggest that a fusion protein between Fab-G8 and the CD3γ chains, once transfected into human PBL, is able to redirect T cells specifically toward MAGE-A1$^+$ melanoma cells (unpublished work). As Fab-G8 already has an affinity 5-

to 500-fold higher than found for TCRs, it will be very interesting to compare the behavior of these Fab-G8-displaying T cells with CTL 82/30 that harbors a natural TCR directed against the same epitope.

To conclude, this work demonstrates that very large human nonimmunized phage libraries can be used to rapidly select antibodies of exquisite TCR-like specificity and highlights the potential of such molecules for immunodiagnostic and immunotherapeutic applications.

1. Hemmila, M. R. & Chang, A. E. (1999) *J. Surg. Oncol.* **70**, 263–274.
2. Gillespie, A. M. & Coleman, R. E. (1999) *Cancer Treat. Rev.* **25**, 219–227.
3. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., de Pleanm, E., van den Eynde, B., Knuth, A. & Boon, T. (1991) *Science* **254**, 1643–1647.
4. Maeurer, M. J., Storkus, W. J., Kirkwood, J. M. & Lotze, M. T. (1996) *Melanoma Res.* **6**, 11–24.
5. Chaux, P., Luiten, R., Demotte, N., Vantomme, V., Stroobant, V., Traversari, C., Russo, V., Schultz, E., Cornelis, G. R., Boon, T., *et al.* (1999) *J. Immunol.* **163**, 2928–2936.
6. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., *et al.* (1999) *Int. J. Cancer* **80**, 219–230.
7. Kariyama, K., Higashi, T., Kobayashi, Y., Nouso, K., Nakatsukasa, H., Yamano, T., Ishizaki, M., Kaneyoshi, T., Toshikuni, N., Ohnishi, T., *et al.* (1999) *Br. J. Cancer* **81**, 1080–1087.
8. Pamer, E. & Cresswell, P. (1998) *Annu. Rev. Immunol.* **16**, 323–358.
9. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Ehring, B., Tampe, R. & Huber, C. (1996) *Clin. Cancer Res.* **2**, 1427–1433.
10. Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G. & Ferrone, S. (1998) *J. Clin. Invest.* **101**, 2720–2729.
11. Wulfing, C. & Pluckthun, A. (1994) *J. Mol. Biol.* **242**, 655–669.
12. Day, P. M., Yewdell, J. W., Porgador, A., Germain, R. N. & Bennink, J. R. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 8064–8069.
13. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germain, R. N. (1997) *Immunity* **6**, 715–726.
14. Zhong, G., Reis e Sousa, C. & Germain, R. N. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 13856–13861.
15. Zhong, G., Sousa, C. R. & Germain, R. N. (1997) *J. Exp. Med.* **186**, 673–682.
16. Dadaglio, G., Nelson, C. A., Deck, M. B., Petzold, S. J. & Unanue, E. R. (1997) *Immunity* **6**, 727–738.
17. Kleijmeer, M. J., Morkowski, S., Griffith, J. M., Rudensky, A. Y. & Geuze, H. J. (1997) *J. Cell Biol.* **139**, 639–649.
18. Eastman, S., Deftos, M., DeRoos, P. C., Hsu, D. H., Teyton, L., Braunstein, N. S., Hackett, C. J. & Rudensky, A. (1996) *Eur. J. Immunol.* **26**, 385–393.
19. Inaba, K., Pack, M., Inaba, M., Sakuta, H., Isdell, F. & Steinman, R. M. (1997) *J. Exp. Med.* **186**, 665–672.
20. Murphy, D. B., Lo, D., Rath, S., Brinster, R. L., Flavell, R. A., Slanetz, A. & Janeway, C. A., Jr. (1989) *Nature (London)* **338**, 765–768.
21. Murphy, D. B., Rath, S., Pizzo, E., Rudensky, A. Y., George, A., Larson, J. K. & Janeway, C. A., Jr. (1992) *J. Immunol.* **148**, 3483–3491.
22. Aharoni, R., Teitelbaum, D., Arnon, R. & Puri, J. (1991) *Nature (London)* **351**, 147–150.
23. Puri, J., Arnon, R., Gurevich, E. & Teitelbaum, D. (1997) *J. Immunol.* **158**, 2471–2476.
24. Reiter, Y., Di Carlo, A., Fugger, L., Engberg, J. & Pastan, I. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 4631–4636.
25. Tamminen, W. L., Wraith, D. & Barber, B. H. (1987) *Eur. J. Immunol.* **17**, 999–1006.
26. Rubin, B., Malissen, B., Jorgensen, P. N. & Zeuthen, J. (1989) *Res. Immunol.* **140**, 67–74.
27. Andersen, P. S., Stryhn, A., Hansen, B. E., Fugger, L., Engberg, J. & Buus, S. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 1820–1824.
28. Garboczi, D. N., Hung, D. T. & Wiley, D. C. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 3429–3433.
29. Barnstable, C. J., Bodmer, W. F., Brown, G., Galfre, G., Milstein, C., Williams, A. F. & Ziegler, A. (1978) *Cell* **14**, 9–20.
30. Seitz, C., Uchanska-Ziegler, B., Zank, A. & Ziegler, A. (1998) *Mol. Immunol.* **35**, 819–827.
31. Hutter, H., Hammer, A., Blaschitz, A., Hartmann, M., Ebbesen, P., Dohr, G., Ziegler, A. & Uchanska-Ziegler, B. (1996) *Cell Tissue Res.* **286**, 439–447.
32. de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruïne, A. P., Arends, J. W. & Hoogenboom, H. R. (1999) *J. Biol. Chem.* **274**, 18218–18230.
33. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D. & Winter, G. (1991) *J. Mol. Biol.* **222**, 581–597.
34. Clackson, T., Hoogenboom, H. R., Griffiths, A. D. & Winter, G. (1991) *Nature (London)* **352**, 624–628.
35. Henderikx, P., Kandilogiannaki, M., Petrarca, C., von Mensdorff-Pouilly, S., Hilgers, J. H., Krambovitis, E., Arends, J. W. & Hoogenboom, H. R. (1998) *Cancer Res.* **58**, 4324–4332.
36. Nieba, L., Nieba-Axmann, S. E., Persson, A., Hamalainen, M., Edebratt, F., Hansson, A., Lidholm, J., Magnusson, K., Karlsson, A. F. & Pluckthun, A. (1997) *Anal. Biochem.* **252**, 217–228.
37. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A. & Boon, T. (1992) *J. Exp. Med.* **176**, 1453–1457.
38. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., *et al.* (1995) *Proc. Natl. Acad. Sci. USA* **92**, 8078–8082.
39. Hu, X., Chakraborty, N. G., Sporn, J. R., Kurtzman, S. H., Ergin, M. T. & Mukherji, B. (1996) *Cancer Res.* **56**, 2479–2483.
40. Engberg, J., Krogsgaard, M. & Fugger, L. (1999) *Immunotechnology* **4**, 273–278.
41. Allan, D. S., Colonna, M., Lanier, L. L., Churakova, T. D., Abrams, J. S., Ellis, S. A., McMichael, A. J. & Braud, V. M. (1999) *J. Exp. Med.* **189**, 1149–1156.
42. O'Callaghan, C. A., Tormo, J., Willcox, B. E., Blundell, C. D., Jakobsen, B. K., Stuart, D. I., McMichael, A. J., Bell, J. I. & Jones, E. Y. (1998) *Protein Sci.* **7**, 1264–1266.
43. Arimilli, S., Cardoso, C., Mukku, P., Baichwal, V. & Nag, B. (1995) *J. Biol. Chem.* **270**, 971–977.
44. Stockel, J., Meinl, E., Hahnel, C., Malotka, J., Seitz, R., Drexler, K., Wekerle, H. & Dornmair, K. (1994) *J. Biol. Chem.* **269**, 29571–29578.
45. Parker, K. C., Carreno, B. M., Sestak, L., Utz, U., Biddison, W. E. & Coligan, J. E. (1992) *J. Biol. Chem.* **267**, 5451–5459.
46. Butler, J. E., Ni, L., Nessler, R., Joshi, K. S., Suter, M., Rosenberg, B., Chang, J., Brown, W. R. & Cantarero, L. A. (1992) *J. Immunol. Methods* **150**, 77–90.
47. Davies, J., Dawkes, A. C., Haymes, A. G., Roberts, C. J., Sunderland, R. F., Wilkins, M. J., Davies, M. C., Tendler, S. J., Jackson, D. E. & Edwards, J. C. (1994) *J. Immunol. Methods* **167**, 263–269.
48. Luescher, I. F., Romero, P., Kuznetsov, D., Rimoldi, D., Coulie, P., Cerottini, J. C. & Jongeneel, C. V. (1996) *J. Biol. Chem.* **271**, 12463–12471.
49. Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A. & Wilson, I. A. (1992) *Science* **257**, 919–927.
50. Davies, D. R., Padlan, E. A. & Sheriff, S. (1990) *Annu. Rev. Biochem.* **59**, 439–473.
51. Hoogenboom, H. R. (1997) *Trends Biotechnol.* **15**, 62–70.
52. Reisfeld, R. A., Becker, J. C. & Gillies, S. D. (1997) *Melanoma Res.* **7**, Suppl. 2, S99–S106.
53. Beun, G. D., van de Velde, C. J. & Fleuren, G. J. (1994) *Immunol. Today* **15**, 11–15.
54. Altenschmidt, U., Kahl, R., Moritz, D., Schnierle, B. S., Gerstmayer, B., Wels, W. & Groner, B. (1996) *Clin. Cancer Res.* **2**, 1001–1008.
55. Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K. & Bolhuis, R. L. (1996) *J. Immunol.* **157**, 836–843.